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I. Introduction
Atrial fibrillation (AF), the most common sustained cardiac
rhythm disturbance, is increasing in prevalence as the popu-
lation ages. Although it is often associated with heart disease,
AF occurs in many patients with no detectable disease.
Hemodynamic impairment and thromboembolic events result
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in significant morbidity, mortality, and cost. Accordingly, the
American College of Cardiology (ACC), the American Heart
Association (AHA), and the European Society of Cardiology
(ESC) created a committee of experts to establish guidelines
for management of this arrhythmia.
The committee was composed of 8 members representing
the ACC and AHA, 4 representing the ESC, 1 from the North
American Society of Pacing and Electrophysiology
(NASPE), and a representative of the Johns Hopkins Univer-
sity Evidence-Based Practice Center representing the Agency
for Healthcare Research and Quality’s report on Atrial
Fibrillation in the Elderly. This document was reviewed by 3
official reviewers nominated by the ACC, 3 nominated by the
AHA, and 3 nominated by the ESC, as well as by the ACC
Clinical Electrophysiology Committee, the AHA ECG and
Arrhythmia Committee, NASPE, and 25 reviewers nomi-
nated by the writing committee. The document was approved
for publication by the governing bodies of the ACC, AHA,
and ESC and officially endorsed by NASPE. These guide-
lines will be reviewed annually by the task force and will be
considered current unless the task force revises or withdraws
them from distribution.
The committee conducted a comprehensive review of the
literature from 1980 to June 2000 relevant to AF using the
following databases: PubMed/Medline, EMBASE, the Co-
chrane Library (including the Cochrane Database of System-
atic Reviews and the Cochrane Controlled Trials Registry),
and Best Evidence. Searches were limited to English lan-
guage sources and to human subjects.
II. Definitions
A. Atrial Fibrillation
AF is a supraventricular tachyarrhythmia characterized by
uncoordinated atrial activation with consequent deterioration
of atrial mechanical function. On the electrocardiogram
(ECG), AF is described by the replacement of consistent
P waves by rapid oscillations or fibrillatory waves that vary in
size, shape, and timing, associated with an irregular, fre-
quently rapid ventricular response when atrioventricular
(AV) conduction is intact (1). The ventricular response to AF
depends on electrophysiological properties of the AV node,
the level of vagal and sympathetic tone, and the action of
drugs (2). Regular RR intervals are possible in the presence of
AV block or interference by ventricular or junctional tachy-
cardia. A rapid, irregular, sustained, wide-QRS-complex
tachycardia strongly suggests AF with conduction over an
accessory pathway or AF with underlying bundle-branch
block. Extremely rapid rates (over 200 bpm) suggest the
presence of an accessory pathway.
B. Related Arrhythmias
AF can be isolated or associated with other arrhythmias, often
atrial flutter or atrial tachycardia. Atrial flutter can arise
during treatment with antiarrhythmic agents prescribed to
prevent recurrent AF. Atrial flutter is more organized than AF,
with a saw-tooth pattern of regular atrial activation called flutter
(f) waves on the ECG, particularly visible in leads II, III, and
aVF. Untreated, the atrial rate typically ranges from 240 to 320
beats per minute (bpm), with f waves inverted in ECG leads II,
III, and aVF and upright in lead V1. The wave of activation in the
right atrium (RA) may be reversed, resulting in f waves that are
upright in leads II, III, and aVF and inverted in lead V1.
Two-to-one AV block is common, producing a ventricular rate
of 120 to 160 bpm. Atrial flutter can degenerate into AF, AF can
initiate atrial flutter, or the ECG pattern can alternate between
atrial flutter and AF, reflecting changing atrial activation.
Other atrial tachycardias, as well as AV reentrant tachy-
cardias and AV nodal reentrant tachycardias, can also trigger
AF. In other atrial tachycardias, P waves are readily identified
and are separated by an isoelectric baseline in 1 or more ECG
leads. The morphology of the P waves can help localize the
origin of atrial tachycardias. A unique type of atrial tachy-
cardia originates in the pulmonary veins (3), is typically more
rapid than 250 bpm, and often degenerates into AF. Intracar-
diac mapping can help differentiate the various atrial arrhyth-
mias.
III. Classification
AF has a heterogeneous clinical presentation, occurring in the
presence or absence of detectable heart disease or related
symptoms. For example, the term “lone AF” has been
variously defined. The prognosis in terms of thromboembo-
lism and mortality is most benign when applied to young
individuals (aged less than 60 years) without clinical or
echocardiographic evidence of cardiopulmonary disease (4).
These patients have a favorable prognosis with respect to
thromboembolism and mortality. By virtue of aging or the
development of cardiac abnormalities, however, patients
move out of the lone AF category over time, and the risks of
thromboembolism and mortality rise. Lone AF is distin-
guished from idiopathic AF, which implies uncertainty about
its origin without reference to the age of the patient or
associated cardiovascular pathology. By convention, the term
nonvalvular AF is restricted to cases in which the rhythm
disturbance occurs in the absence of rheumatic mitral stenosis
or a prosthetic heart valve.
The classification scheme recommended in this document
represents a consensus driven by a desire for simplicity and
clinical relevance. The clinician should distinguish a first-
detected episode of AF, whether or not it is symptomatic or
self-limited, recognizing that there can be uncertainty about
the duration of the episode and about previous undetected
episodes (Fig. 1). When a patient has had 2 or more episodes,
AF is considered recurrent. Once terminated, recurrent AF is
designated paroxysmal, and when sustained, persistent. In the
latter case, termination by pharmacological therapy or elec-
trical cardioversion does not change the designation. Persis-
tent AF can be either the first presentation or a culmination of
recurrent episodes of paroxysmal AF. Persistent AF includes
cases of long-standing AF (eg, greater than 1 year), in which
cardioversion has not been indicated or attempted, usually
leading to permanent AF (Fig. 1). The terminology defined in
the preceding paragraph applies to episodes of AF that last
more than 30 seconds and that are unrelated to a reversible
cause. AF secondary to a precipitating condition such as acute
myocardial infarction, cardiac surgery, myocarditis, hyper-
thyroidism, or acute pulmonary disease is considered sepa-
rately. In these settings, treatment of the underlying disorder
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concurrently with management of the episode of AF usually
eliminates the arrhythmia.
IV. Epidemiology and Prognosis
AF is the most common clinically significant cardiac arrhyth-
mia. In one series, AF accounted for 34.5% of patients
hospitalized with a cardiac rhythm disturbance (5). It has
been estimated that 2.2 million Americans have paroxysmal
or persistent AF (6).
A. Prevalence
The prevalence of AF is estimated at 0.4% of the general
population, increasing with age (7). AF is uncommon in
childhood except after cardiac surgery. It occurs in fewer than
1% of those under 60 years of age but in more than 6% of
those over 80 years of age (8–10) (Fig. 2). The age-adjusted
prevalence is higher in men (10,11). Blacks have less than
half the age-adjusted risk of developing AF that is seen in
whites (12). The frequency of lone AF was less than 12% of
all cases of AF in some series (4,10,13,14) but over 30% in
others (15,16). The prevalence of AF increases with the
severity of congestive heart failure (HF) or valvular heart
disease.
B. Prognosis
The rate of ischemic stroke among patients with nonrheu-
matic AF averages 5% per year, which is 2 to 7 times the rate
for people without AF (8,9,15,17–19) (Fig. 3). One of every
6 strokes occurs in patients with AF (20). Including transient
ischemic attacks and clinically silent strokes detected radio-
graphically, the rate of brain ischemia accompanying nonval-
vular AF exceeds 7% per year (21–25). In the Framingham
Heart Study, patients with rheumatic heart disease and AF
had a 17-fold increased risk of stroke compared with age-
matched controls (26), and the attributable risk was 5 times
greater than in those with nonrheumatic AF (9). Among AF
patients from general practices in France, the ALFA Study
(Etude en Activite´ Liberale sur le Fibrillation Auriculaire)
found a 2.4% incidence of thromboembolism over a mean of
8.6 months of follow-up (15). The annual risk of stroke
attributable to AF increased from 1.5% in Framingham Study
participants aged 50 to 59 years to 23.5% for those aged 80 to
89 years (9). The total mortality rate is approximately doubled in
patients with AF compared with patients in normal sinus rhythm
and is linked with the severity of underlying heart disease
(8,11,18) (Fig. 3).
V. Pathophysiological Mechanisms
A. Atrial Factors
1. Pathology of the Atrium in Patients With AF
The atria of patients with persistent AF display structural
abnormalities beyond those caused by underlying heart dis-
ease (27). Patchy fibrosis with juxtaposition of normal and
diseased atrial fibers may account for nonhomogeneity of
atrial refractoriness (28,29). Fibrosis or fatty infiltration can
also affect the sinus node and might be a reaction to
inflammatory or degenerative processes that are difficult to
detect. The role of inflammation in the pathogenesis of AF
has not yet been evaluated, but histological changes consis-
tent with myocarditis were reported in 66% of biopsy specimens
from patients with lone AF (29). Infiltration of the atrial
Figure 1. Patterns of atrial fibrillation. 1, episodes that generally last less than or equal to 7 days (most less than 24 h); 2, usually more
than 7 days; 3, cardioversion failed or not attempted; and 4, either paroxysmal or persistent AF may be recurrent.
Figure 2. Prevalence of AF in 2 American epidemiological stud-
ies. Framingham indicates the Framingham Heart Study (9);
CHS, Cardiovascular Health Study (10).
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myocardium can occur in amyloidosis, sarcoidosis, and hemo-
chromatosis. Atrial fiber hypertrophy has been described as a
major and sometimes the sole histological feature (28). Progres-
sive atrial dilatation has been demonstrated echocardiographi-
cally in patients with AF (30) and, like hypertrophy, can be
either a cause or a consequence of persistent AF.
2. Mechanisms of AF
Theories of the mechanism of AF involve 2 main pro-
cesses: enhanced automaticity in 1 or several rapidly depo-
larizing foci and reentry involving 1 or more circuits (31,32).
Rapidly firing atrial foci, located in 1 or several of the
superior pulmonary veins, can initiate AF in susceptible
patients (3,33). Foci also occur in the RA and infrequently in
the superior vena cava or coronary sinus (3,33,34). The focal
origin appears to be more important in paroxysmal AF than in
persistent AF. Ablation of such foci can be curative (3).
The multiple-wavelet hypothesis as the mechanism of
reentrant AF was advanced by Moe and colleagues (31,35),
who proposed that fractionation of the wave fronts as they
propagate through the atria results in self-perpetuating
“daughter wavelets.” The number of wavelets present at any
time depends on the refractory period, mass, and conduction
velocity in different parts of the atria.
Although the patterns of activation underlying the irregular
atrial electrical activity of AF have traditionally been de-
scribed as disorganized or random, recent evidence has
emerged that AF is spatially organized. Based on mapping
studies of patients undergoing surgery for the Wolff-
Parkinson-White (WPW) syndrome, 3 patterns of induced AF
have been identified (36). Type I AF involves single wave
fronts propagating across the RA. Type II AF involves 1 or 2
wave fronts, and type III AF is characterized by multiple
activation wavelets propagating in different directions. Ulti-
mately, a better understanding of electrophysiological mech-
anisms will lead to the development of effective preventive
measures (37).
B. AV Conduction
1. General Aspects
The AV node is ordinarily the factor that limits conduction
during AF. The compact AV node is located anteriorly in the
triangle of Koch (38), surrounded by transitional cells. There
appear to be 2 distinct atrial inputs to the AV node, posteri-
orly via the crista terminalis and anteriorly via the interatrial
septum. Studies on rabbit AV nodal preparations show that
during AF, propagation of impulses through the AV node to
the His bundle depends in part on the relative timing of the
anterior and posterior septal activation inputs to the AV node
(39). Other factors that affect conduction through the AV
node are its intrinsic conduction and refractoriness, concealed
conduction, and autonomic tone.
2. AV Conduction in the WPW Syndrome
Accessory pathways are muscle connections between the
atrium and ventricle that have the capacity to conduct rapidly.
Conduction over an accessory pathway during AF can result
in a very rapid ventricular response that can be fatal (2,40).
Drugs such as digitalis, calcium channel antagonists, and
beta-blockers, which are usually given to slow conduction
across the AV node during AF, do not block conduction over
the accessory pathway and can even enhance conduction,
resulting in hypotension or cardiac arrest (41). Patients who
develop AF with a rapid ventricular response associated with
hemodynamic instability that results from conduction over an
accessory pathway should undergo immediate electrical car-
dioversion. In the absence of hemodynamic instability or a
preexcited ventricular response, intravenous procainamide
and ibutilide are drugs of choice to achieve pharmacological
cardioversion or to block conduction over the accessory
pathway.
C. Myocardial and Hemodynamic Consequences
of AF
During AF, 3 factors can affect hemodynamic function: loss
of synchronous atrial mechanical activity, irregularity of
ventricular response, and inappropriately rapid heart rate. A
marked decrease in cardiac output can occur with the loss of
atrial contraction, especially in patients with impaired dia-
stolic ventricular filling, hypertension, mitral stenosis, hyper-
trophic cardiomyopathy (HCM), or restrictive cardiomyopa-
thies. The variation in RR intervals during AF can also result
in hemodynamic impairment. A persistently rapid atrial rate
can adversely affect atrial mechanical function (tachycardia-
Figure 3. Relative risk of stroke and mortality in patients with AF compared with patients without AF. Source data are from the Fra-
mingham Heart Study (11), Regional Heart Study (8), Whitehall study (8), and Manitoba study (18).
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induced atrial cardiomyopathy) (2,42). Such changes in atrial
tissue might explain the delayed recovery of atrial contractil-
ity in patients after cardioversion to sinus rhythm.
A persistently elevated ventricular rate during AF (130
bpm or faster in one study) (43) can produce dilated ventric-
ular cardiomyopathy (2,43–46). It is critically important to
recognize tachycardia-induced cardiomyopathy, because con-
trol of the ventricular rate can lead to partial or even complete
reversal of the myopathic process. In fact, HF can be the
initial manifestation of AF. A variety of hypotheses have
been proposed to explain tachycardia-mediated cardiomyop-
athy that involve myocardial energy depletion, ischemia,
abnormalities of calcium regulation, and remodeling, but the
actual mechanisms responsible for this disorder are still
unclear (47).
D. Thromboembolism
Although ischemic stroke and systemic arterial occlusion in
AF are generally attributed to embolism from the left atrium
(LA), the pathogenesis of thromboembolism is complex (48).
Up to 25% of AF-associated strokes can be due to intrinsic
cerebrovascular diseases, other cardiac sources of embolism,
or atheromatous pathology in the proximal aorta (49,50).
About half of elderly AF patients have chronic hypertension
(a major risk factor for cerebrovascular disease) (19), and
approximately 12% harbor cervical carotid artery stenosis.
Carotid atherosclerosis is not substantially more prevalent in
AF patients with stroke than in patients without AF, however,
and is probably a relatively minor contributing factor (51).
1. Pathophysiology of Thrombus Formation
Thrombus associated with AF arises most frequently in the
LA appendage (LAA). This cannot be examined reliably by
precordial (transthoracic) echocardiography (52), whereas
transesophageal Doppler echocardiography provides a sensi-
tive and specific method to assess LAA function (53) and to
detect thrombotic material. LAA flow velocities are reduced
because of loss of organized mechanical contraction during
AF (54,55). This substrate of decreased flow within the
LA/LAA has been associated with spontaneous echo contrast,
thrombus formation, and embolic events (56–62). LAA flow
velocities are lower in patients with atrial flutter than what is
usually seen with normal sinus rhythm but are higher than
with AF. Whether this accounts for the slightly lower prev-
alence of LAA thrombus and perhaps a lower rate of
thromboembolism associated with atrial flutter is uncertain.
In patients with AF, independent predictors of spontaneous
echo contrast include LA size, LAA flow velocity (56,63),
left ventricular (LV) dysfunction, fibrinogen level (62), he-
matocrit (61,62), and aortic atherosclerosis (61,62,64,65).
This phenomenon might be an echocardiographic surrogate
for regional coagulopathy and, when dense, is of clinical
value to identify AF patients at high risk for thromboembo-
lism (64), but its utility for prospective risk stratification for
thromboembolism beyond that achieved by clinical assess-
ment has not been established. Although conventional clinical
management is based on the presumption that thrombus
formation requires continuation of AF for approximately
48 h, thrombi have been identified by transesophageal echo-
cardiography (TEE) within shorter intervals (66,67).
Contrary to the prevalent view that systemic anticoagula-
tion for 4 weeks results in endocardial adherence and orga-
nization of LAA thrombus, TEE studies have verified reso-
lution of thrombus in the majority of patients (68). Similar
observations have defined the transient nature of LA/LAA
dysfunction on conversion of AF, which provides a mecha-
nistic rationale for anticoagulation for several weeks before
and after successful cardioversion.
2. Clinical Implications
Because the pathophysiology of thromboembolism in pa-
tients with AF is uncertain, the mechanisms that link risk
factors to ischemic stroke in AF are also incompletely
defined. The strong association between hypertension and
stroke in AF is probably mediated primarily by embolism that
originates in the LAA (49), but hypertension also increases
the risk of noncardioembolic strokes in AF (49,69). Hyper-
tension in AF patients is associated with reduced LAA flow
velocity and spontaneous echo contrast, which predisposes
the patient to thrombus formation (63,64,70). Ventricular
diastolic dysfunction might underlie the effect of hyperten-
sion on LA dynamics (71,72). The effect of advancing age to
increase stroke risk in AF is multifactorial. In patients with
AF, aging is associated with LA enlargement, reduced LAA
flow velocity, and spontaneous echo contrast, each of which
predisposes to LA thrombus formation (30,63,64). Addition-
ally, age is a risk factor for atherosclerosis, including com-
plex aortic arch plaque, and is associated with stroke inde-
pendently of AF (65). LV systolic dysfunction predicts
ischemic stroke in AF patients receiving no antithrombotic
therapy (73–76).
VI. Associated Conditions, Clinical
Manifestations, and Quality of Life
A. Causes and Associated Conditions
1. Acute Causes of AF
AF can be related to acute, temporary causes, including
alcohol intake, surgery, electrocution, myocarditis, pulmo-
nary embolism, other pulmonary diseases, and hyperthyroid-
ism. Successful treatment of the underlying condition can
eliminate AF. AF is a common early postoperative compli-
cation of myocardial infarction and of cardiac or thoracic
surgery.
2. AF Without Associated Cardiovascular Disease
In younger patients, approximately 30% to 45% of parox-
ysmal cases and 20% to 25% of persistent cases of AF occur
as lone AF (13,15,16).
3. AF With Associated Cardiovascular Disease
Specific cardiovascular conditions associated with AF
include valvular heart disease (most often mitral), coronary
artery disease (CAD), and hypertension, particularly when
LV hypertrophy (LVH) is present.
4. Neurogenic AF
The autonomic nervous system can trigger AF in suscep-
tible patients through heightened vagal or adrenergic tone.
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Many patients experience onset of AF during periods of
enhanced parasympathetic or sympathetic tone. Coumel
(77) described a group of patients that he characterized in
terms of a vagal or adrenergic form of AF. Patients with
pure vagal or adrenergic AF are uncommon, but if the
history reveals a pattern of onset of AF with features of
one of these syndromes, the clinician can select agents
more likely to prevent recurrent episodes.
B. Clinical Manifestations
AF can be symptomatic or asymptomatic, even in the same
patient. Symptoms vary with the ventricular rate, underlying
functional status, duration of AF, and individual patient
perceptions. The dysrhythmia can present for the first time
with an embolic complication or exacerbation of HF. Most
patients with AF complain of palpitations, chest pain, dys-
pnea, fatigue, or lightheadedness. Release of atrial natri-
uretic peptide can be associated with polyuria. AF can lead
to tachycardia-mediated cardiomyopathy, especially in
patients who are unaware of the arrhythmia. Syncope is an
uncommon but serious complication that usually indicates
sinus node dysfunction, valvular aortic stenosis, HCM,
cerebrovascular disease, or an accessory AV pathway.
C. Quality of Life
Although strokes certainly account for much of the functional
impairment associated with AF, the rhythm disturbance also
decreases quality of life. In the Stroke Prevention in Atrial
Fibrillation (SPAF) study cohort, the New York Heart Associ-
ation functional classification, developed for HF, was an insen-
sitive index of quality of life in patients with AF (78). In another
study (79), 47 (68%) of 69 patients with paroxysmal AF
considered the dysrhythmia disruptive of their lives. This per-
ception was not associated with either the frequency or duration
of symptoms. The AFFIRM trial (Atrial Fibrillation Follow-up
Investigation of Rhythm Management), which is still in
progress, is comparing maintenance of sinus rhythm with rate
control in patients with AF, addressing many facets of quality of
life, as did the smaller PIAF (Pharmacological Intervention in
Atrial Fibrillation) study (80). In selected patients, radiofre-
quency catheter ablation of the AV node and pacemaker inser-
tion improved quality-of-life scores compared with medical
therapy (81–86).
Long-term oral anticoagulant therapy, which involves fre-
quent blood testing and multiple drug interactions, is another
factor with important implications for the quality of life of AF
patients. Decision analysis found that only 61% of 97 patients
preferred anticoagulation therapy to no treatment (87), a
considerably smaller proportion than that for whom treatment
has been recommended according to published guidelines.
VII. Clinical Evaluation
A. Minimum Evaluation of the Patient With AF
1. Clinical History and Physical Examination
The initial evaluation of a patient with suspected or proven
AF includes characterizing the pattern of the arrhythmia as
paroxysmal or persistent, determining its cause, and defining
associated cardiac and extracardiac factors (Table 1). A careful
history will result in a well-planned, focused workup that serves
as an effective guide to therapy (2). The workup of an AF patient
can usually take place and therapy can be initiated in 1 outpatient
encounter. Delay occurs when the rhythm has not been specif-
ically documented and additional monitoring is necessary.
The physical examination may suggest AF on the basis of
irregular pulse, irregular jugular venous pulsations, and vari-
ation in the loudness of the first heart sound. Examination
may also disclose associated valvular heart disease, myocar-
dial abnormalities, or HF. The findings on examination are
similar in patients with atrial flutter, except that the rhythm
may be regular and rapid venous oscillations may occasion-
ally be visible in the jugular pulse.
2. Investigations
The diagnosis of AF requires ECG documentation by at least
single-lead ECG recording during the dysrhythmia, which may
be facilitated by review of emergency department records,
Holter monitoring, or transtelephonic or telemetric recordings. A
portable ECG recording tool may help establish the diagnosis in
cases of paroxysmal AF and provide a permanent ECG record of
the dysrhythmia. If episodes are frequent, then a 24-h Holter
monitor can be used. If episodes are infrequent, then an event
recorder, which allows the patient to transmit the ECG to a
recording facility when the arrhythmia occurs, may be more
useful.
B. Additional Investigation of Selected Patients
With AF
Additional investigation may include Holter monitoring
and exercise testing, transesophageal echocardiography,
and/or electrophysiological study. See Table 1 for details.
VIII. Management
The major issues in management of patients with AF are
related to the arrhythmia itself and to prevention of throm-
boembolism. In patients with persistent AF, there are funda-
mentally 2 ways to manage the dysrhythmia: to restore and
maintain sinus rhythm or to allow AF to continue and ensure
that the ventricular rate is controlled.
A. Rhythm Control vs Heart Rate Control
Reasons for restoration and maintenance of sinus rhythm in
patients with AF include relief of symptoms, prevention of
embolism, and avoidance of cardiomyopathy.
B. Cardioversion
1. Basis for Cardioversion of AF
Cardioversion is often performed electively to restore sinus
rhythm in patients with persistent AF. The need for cardio-
version can be immediate, however, when the arrhythmia is
the main factor responsible for acute HF, hypotension, or
worsening of angina pectoris in a patient with CAD. Never-
theless, cardioversion carries a risk of thromboembolism
unless anticoagulation prophylaxis is initiated before the
procedure, and this risk appears to be greatest when the
arrhythmia has been present more than 48 h.
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TABLE 1. Minimum and Additional Clinical Evaluation of Patients With Atrial Fibrillation
Minimum evaluation
1. History and physical examination, to define
• The presence and nature of symptoms associated with AF
• The clinical type of AF (first episode, paroxysmal, persistent, or permanent)
• The onset of the first symptomatic attack or date of discovery of AF
• The frequency, duration, precipitating factors, and modes of termination of AF
• The response to any pharmacological agents that have been administered
• The presence of any underlying heart disease or other reversible conditions (eg, hyperthyroidism or alcohol
consumption)
2. Electrocardiogram, to identify
• Rhythm (verify AF)
• LV hypertrophy
• P-wave duration and morphology or fibrillatory waves
• Preexcitation
• Bundle-branch block
• Prior MI
• Other atrial arrhythmias
• To measure and follow the RR, QRS, and QT intervals in conjunction with antiarrhythmic drug therapy
3. Chest radiograph, to evaluate
• The lung parenchyma, when clinical findings suggest an abnormality
• The pulmonary vasculature, when clinical findings suggest an abnormality
4. Echocardiogram, to identify
• Valvular heart disease
• Left and right atrial size
• LV size and function
• Peak RV pressure (pulmonary hypertension)
• LV hypertrophy
• LA thrombus (low sensitivity)
• Pericardial disease
5. Blood tests of thyroid function
• For a first episode of AF, when the ventricular rate is difficult to control, or when AF recurs unexpectedly
after cardioversion
Additional testing
• One or several tests may be necessary
1. Exercise testing
• If the adequacy of rate control is in question (permanent AF)
• To reproduce exercise-induced AF
• To exclude ischemia before treatment of selected patients with a type IC antiarrhythmic drug
2. Holter monitoring or event recording
• If diagnosis of the type of arrhythmia is in question
• As a means of evaluating rate control
3. Transesophageal echocardiography
• To identify LA thrombus (in the LA appendage)
• To guide cardioversion
4. Electrophysiological study
• To clarify the mechanism of wide-QRS-complex tachycardia
• To identify a predisposing arrhythmia such as atrial flutter or paroxysmal supraventricular tachycardia
• Seeking sites for curative ablation or AV conduction block/modification
AF indicates atrial fibrillation; LV, left ventricular; MI, myocardial infarction; RV, right ventricular; LA, left atrial; and AV,
atrioventricular. Type IC refers to the Vaughan Williams classification of antiarrhythmic drugs (see Table 2).
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2. Methods of Cardioversion
Cardioversion can be achieved by means of drugs or
electrical shocks. Drugs were commonly used before electri-
cal cardioversion became a standard procedure. The develop-
ment of new drugs has increased the popularity of pharma-
cological cardioversion, although some disadvantages persist,
including the risk of drug-induced torsade de pointes ventric-
ular tachycardia or other serious arrhythmias. Pharmacolog-
ical cardioversion is still less effective than electrical cardio-
version, but the latter requires conscious sedation or
anesthesia, whereas the former does not.
The risk of thromboembolism or stroke does not differ
between pharmacological and electrical cardioversion. Thus,
recommendations for anticoagulation are the same for both
methods.
C. Pharmacological Cardioversion
Pharmacological cardioversion appears to be most effective
when initiated within 7 days after the onset of AF (88–91).
Most such patients have paroxysmal AF, a first-documented
episode of AF, or an unknown pattern of AF at the time of
treatment. (See Section III, Classification.) A large proportion
of patients with recent-onset AF experience spontaneous
cardioversion within 24 to 48 h (92–94). This is less likely to
occur when AF has persisted for more than 7 days.
The relative efficacy of various drugs differs for pharma-
cological cardioversion of AF and atrial flutter, yet many
studies of drug therapy for AF have included patients with
atrial flutter. The dose, route, and rapidity of administration
influence efficacy. Reference is made to the Vaughan Wil-
liams classification of antiarrhythmic drugs (95), which has
been modified to include recently available drugs (Table 2).
A summary of recommendations is presented in Tables 10
through 12 (see Section IX-B, Recommendations for Phar-
macological and Electrical Cardioversion of AF, Tables
10–12). Although clinical use of the antiarrhythmic drugs
listed has been approved by regulatory agencies, therapeutic
use for AF has not been mentioned or approved in all cases in
each country. The recommendations given in this document
do not necessarily adhere to governmental regulations and
labeling requirements.
A frequent issue related to pharmacological cardioversion
is whether the antiarrhythmic drug should be started in the
hospital or on an outpatient basis. The major concern is the
potential for serious adverse effects, including torsade de
pointes ventricular tachycardia. With the exception of those
involving low-dose oral amiodarone (96), virtually all studies
of pharmacological cardioversion have been limited to hos-
pitalized patients.
D. Electrical Cardioversion
Direct-current cardioversion involves an electrical shock
synchronized with the intrinsic activity of the heart. This
ensures that electrical stimulation does not occur during the
vulnerable phase of the cardiac cycle (97).
Successful cardioversion of AF depends on the nature of
the underlying heart disease and the current density delivered
to the atrial myocardium. The latter, in turn, depends on the
voltage of the defibrillator capacitor, the output waveform,
the size and position of the electrode paddles, and trans-
thoracic impedance.
In a randomized controlled study of 301 subjects undergo-
ing elective external cardioversion, patients were allocated to
anterior-lateral (ventricular apex and right infraclavicular) or
anterior-posterior (sternum and left scapular) paddle positions
(98). The energy requirement was lower and overall success
was greater with the anterior-posterior configuration (87%)
than with the anterior-lateral alignment (76%).
Cardioversion is performed with the patient having fasted
and under adequate anesthesia. Short-acting anesthetic agents
are preferred, because cardioversion patients are well suited
to day care and should recover rapidly after the procedure
(99).
An initial shock of 100 J is often too low, and an initial
energy of 200 J or greater is recommended for electrical
cardioversion of AF. Devices that deliver current with a
biphasic waveform appear to achieve cardioversion at lower
energy levels than those that use a monophasic waveform.
The primary success rate as measured 3 days after cardiover-
sion in 100 consecutive subjects was 86% (100); this in-
creased to 94% when the procedure was repeated during
treatment with quinidine or disopyramide. Only 23% of the
patients remained in sinus rhythm after 1 year and 16% after
2 years; in those who relapsed, repeated cardioversion with
antiarrhythmic medication resulted in sinus rhythm in 40%
and 33% after 1 and 2 years, respectively. For patients who
relapsed again, a third cardioversion resulted in sinus rhythm
TABLE 2. Vaughan Williams Classification of Antiarrhythmic
Drug Actions
Type IA
Disopyramide
Procainamide
Quinidine
Type IB
Lidocaine
Mexiletine
Type IC
Flecainide
Moricizine
Propafenone
Type II
Beta-blockers (e.g., propranolol)
Type III
Amiodarone
Bretylium
Dofetilide
Ibutilide
Sotalol
Type IV
Calcium-channel antagonists (e.g., verapamil and diltiazem)
Modified with permission from Vaughn Williams EM. A classification of
antiarrhythmic action as reassessed after a decade of new drugs. J Clin
Pharmacol 1984;24:129–47, © 1984 by Sage Publications Inc. (95) to include
compounds introduced after publication of the original classification.
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in 54% at 1 year and 41% at 2 years. Thus, sinus rhythm can
be restored in a substantial proportion of patients by direct-
current cardioversion, but the rate of relapse is high unless
antiarrhythmic drug therapy is given concomitantly.
Cardioversion of patients with implanted pacemaker and
defibrillator devices is safe when appropriate precautions are
taken. The device should be interrogated immediately before
and after cardioversion to verify appropriate function. The
paddles used for external cardioversion should be positioned
as distant as possible from the device, preferably in the
anterior-posterior configuration.
The risks of electrical cardioversion are mainly related to
embolic events and cardiac arrhythmias. Thromboembolic
events have been reported in 1% to 7% of patients who did
not receive anticoagulation before cardioversion (101,102).
Various brief arrhythmias might arise, especially ventricular
and supraventricular premature beats, bradycardia, and short
periods of sinus arrest (103). Ventricular tachycardia and
fibrillation can be precipitated in patients with hypokalemia
or digitalis intoxication (104,105). A slow ventricular re-
sponse to AF in the absence of drugs that slow AV nodal
conduction can indicate conduction defect. The patient should
be evaluated before cardioversion with these issues in mind to
avoid symptomatic bradycardia (106). Transient ST-segment
elevation can appear on the ECG after cardioversion (107–
108) and blood levels of creatine kinase-MB can rise even
without apparent myocardial damage.
Prophylactic drug therapy to prevent early recurrence of
AF should be considered individually for each patient. Should
relapse (particularly early relapse) occur, antiarrhythmic ther-
apy is recommended in conjunction with the second attempt.
Further cardioversion is of limited value. In highly symptom-
atic patients, infrequently repeated cardioversion can be an
acceptable approach.
E. Maintenance of Sinus Rhythm
1. Pharmacological Therapy to Prevent Recurrence
of AF
Maintenance of sinus rhythm is relevant in patients with
paroxysmal AF (in whom episodes terminate spontaneously)
and persistent AF (in whom electrical or pharmacological
cardioversion is necessary to restore sinus rhythm). Whether
paroxysmal or persistent, AF is a chronic disorder, and
recurrence is likely at some point in most patients (Fig. 4)
(109,110). Prophylactic treatment with antiarrhythmic drugs
is therefore often necessary. The goal of maintenance therapy
is suppression of symptoms and sometimes prevention of
tachycardia-induced cardiomyopathy due to AF. It is not yet
known whether maintenance of sinus rhythm prevents throm-
boembolism, HF, or death (80,111).
Recurrence of AF is not equivalent to treatment failure. In
several studies (112,113), patients with recurrent AF often
chose to continue drug treatment. Sometimes, reduction of
the arrhythmia burden can constitute partial success, whereas
to other patients, any recurrence of AF may seem intolerable.
Nevertheless, most patients with AF eventually experience
recurrence. Risk factors for frequent recurrence of paroxys-
mal AF (more than 1 episode per month) include female sex
and underlying heart disease (114). In persistent AF, the
4-year arrhythmia-free survival was less than 10% after
single-shock electrical cardioversion without prophylactic
drug therapy (110). Predictors of recurrences within that
interval included hypertension, age greater than 55 years, and
AF duration greater than 3 months. In that study, serial
cardioversions and prophylactic drug therapy resulted in
freedom from recurrent AF in only approximately 30% of
patients (110). Predictors of recurrence included age greater
than 70 years, AF duration greater than 3 months, and HF
(110).
2. General Approach to Antiarrhythmic Drug Therapy
Before any antiarrhythmic agent is administered, reversible
cardiovascular and noncardiovascular precipitants of AF
should be addressed. Prophylactic drug treatment is seldom
indicated in case of a first-detected episode of AF and can
also be avoided in patients with infrequent and well-tolerated
paroxysmal AF. Similarly, when recurrences are infrequent
and tolerated, patients experiencing breakthrough arrhyth-
mias might not require a change in antiarrhythmic drug
therapy. Beta-blockers can be effective in patients who
develop AF only during exercise, but few patients have a
single specific inciting cause for all episodes of AF, and a
majority will not sustain sinus rhythm without antiarrhythmic
drug treatment.
In patients with lone AF, a beta-blocker may be tried first,
but flecainide, propafenone, and sotalol are particularly ef-
fective. Amiodarone and dofetilide are recommended as
alternative therapy. Quinidine, procainamide, and disopyr-
Figure 4. Arrhythmia-free survival after electrical cardioversion
in patients with persistent atrial fibrillation. The lower curve rep-
resents outcome after a single shock when no prophylactic drug
therapy was given. The upper curve depicts the outcome with
repeated electrical cardioversions in conjunction with antiar-
rhythmic drug prophylaxis. ECV indicates electrical cardiover-
sion; SR, sinus rhythm. Reproduced with permission from van
Gelder et al., Arch Intern Med 1996;156:2585–92, © 1996,
American Medical Association (110).
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amide are not favored unless amiodarone fails or is contra-
indicated. The anticholinergic activity of long-acting disopyr-
amide makes this a relatively attractive choice for patients
with a predilection to vagally induced AF. Propafenone is not
recommended in vagally mediated AF because its (weak)
intrinsic beta-blocking activity might aggravate this type of
paroxysmal AF. In patients with adrenergically mediated AF,
beta-blockers represent first-line treatment, followed by so-
talol and amiodarone. In patients with adrenergically medi-
ated lone AF, amiodarone should be chosen later in the
sequence of drug therapy because of its potential toxicity (see
Fig. 11, Section IX). Overall, when treatment with a single
drug fails, combinations of antiarrhythmic drugs may be
tried. Useful combinations include a beta-blocker, sotalol or
amiodarone, plus a type IC agent.
A drug that is initially safe might become proarrhythmic
when the patient develops CAD or HF or begins taking other
medication that in combination can be arrhythmogenic. Thus,
the patient should be alerted to the potential significance of
such symptoms as syncope, angina pectoris, or dyspnea and
warned about the use of noncardiac drugs that can prolong the
QT interval. A useful source of information is the Internet site
http://www.torsades.org.
Monitoring of antiarrhythmic drug treatment varies with
the agent involved and with patient factors. Prospective trial
data on upper limits of drug-induced increases in QRS
duration or QT prolongation are not available. The following
recommendations are the consensus of the writing committee.
With type IC drugs, QRS widening should not exceed 150%
of the pretreatment QRS duration. Exercise testing can be
helpful to detect QRS widening that occurs only at rapid heart
rates (use-dependent conduction slowing). For type IA or
type III drugs, with the possible exception of amiodarone, the
corrected QT interval in sinus rhythm should remain below
520 ms. During follow-up, plasma potassium and magnesium
levels and renal function should be checked periodically,
because renal insufficiency leads to drug accumulation and
predisposes to proarrhythmia. In individual patients, serial
noninvasive tests can be appropriate to reevaluate LV func-
tion, especially if clinical HF develops during treatment of
AF.
3. Pharmacological Agents to Maintain Sinus Rhythm
Fourteen controlled trials of drug prophylaxis involving
patients with paroxysmal AF have been published, and there
have been 22 published trials of drug prophylaxis for main-
tenance of sinus rhythm in patients with persistent AF.
Comparative data are not sufficient to permit subclassifica-
tion by drug or etiology. Individual drugs and dosages for
maintenance of sinus rhythm are given in Table 3.
4. Out-of-Hospital Initiation of Antiarrhythmic Drugs in
Patients With AF
Recommendations for out-of-hospital initiation or intermit-
tent use of antiarrhythmic drugs differ for patients with
paroxysmal and persistent AF. In patients with paroxysmal
AF, the aims are to stop an attack, to prevent recurrences, or
a combination of both. In patients with persistent AF, the
aims of out-of-hospital drug initiation are to achieve pharma-
cological cardioversion of AF, thereby obviating the need for
electrical cardioversion, or to enhance the success of electri-
cal cardioversion and prevent early recurrence of AF.
Few prospective data are available on the safety of outpa-
tient initiation of antiarrhythmic drug therapy. Proarrhythmia
(Table 4) is rare in patients with normal ventricular function
and baseline QT intervals (41,115) without profound brady-
cardia. As long as sinus or AV node dysfunction is not
suspected, propafenone or flecainide may be initiated out of
hospital. Sudden death related to idiopathic ventricular fibril-
TABLE 3. Typical Doses of Drugs Used to Maintain Sinus Rhythm in Patients With
Atrial Fibrillation**
Drug* Daily Dosage Potential Adverse Effects
Amiodarone† 100–400 mg Photosensitivity, pulmonary toxicity, polyneuropathy,
GI upset, bradycardia, torsade de pointes (rare),
hepatic toxicity, thyroid dysfunction
Disopyramide 400–750 mg Torsade de pointes, HF, glaucoma, urinary retention,
dry mouth
Dofetilide‡ 500–1000 mcg Torsade de pointes
Flecainide 200–300 mg Ventricular tachycardia, congestive HF, enhanced AV nodal
conduction (conversion to atrial flutter)
Procainamide 1000–4000 mg Torsade de pointes, lupus-like syndrome, GI symptoms
Propafenone 450–900 mg Ventricular tachycardia, congestive HF, enhanced AV nodal
conduction (conversion to atrial flutter)
Quinidine 600–1500 mg Torsade de pointes, GI upset, enhanced AV nodal conduction
Sotalol‡ 240–320 mg Torsade de pointes, congestive HF, bradycardia,
exacerbation of chronic obstructive or bronchospastic
lung disease
GI indicates gastrointestinal; AV, atrioventricular; and HF, heart failure.
*Drugs are listed alphabetically.
**The drugs and doses given here have been determined by consensus based on published studies.
†A loading dose of 600 mg per day is usually given for one month or 1000 mg per day over 1 week.
‡Dose should be adjusted for renal function and QT-interval response during in-hospital initiation phase.
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lation in a structurally normal heart can occur in patients with
the Brugada syndrome, an inherited cardiac disease charac-
terized by ST-segment elevation in the right precordial ECG
leads and frequently accompanied by right bundle-branch
block. Type I antiarrhythmic drugs can unmask this condition
(116,117). Before therapy with these agents is begun, a
beta-blocker or calcium channel antagonist should be given to
prevent rapid AV conduction or 1:1 AV conduction if atrial
flutter develops (118–122). Because termination of paroxys-
mal AF with flecainide or propafenone can be associated with
bradycardia due to sinus node or AV node dysfunction, an initial
conversion should be undertaken in the hospital before a patient
is declared fit for outpatient “pill-in-the pocket” use of these
agents for conversion of recurrences. Out-of-hospital drug ter-
mination should be avoided in patients with symptomatic sick
sinus syndrome, AV conduction disturbances, or bundle-branch
block.
Sotalol may be initiated in outpatients with little or no heart
disease as long as the baseline uncorrected QT interval is less
than 450 ms, serum electrolytes are normal, and none of the
type III drug-related proarrhythmia risk factors are present.
Safety is greatest when sotalol is started when the patient is in
sinus rhythm. Amiodarone can usually be given safely on an
outpatient basis, even in patients with persistent AF (123), but
in-hospital loading might be more appropriate when earlier
restoration of sinus rhythm is needed, as in patients with HF.
Some loading regimens involve giving either 600 mg per day for
4 weeks (123) or greater than or equal to 1 g per day for 1 week
(124) followed by lower maintenance doses. Quinidine, procain-
amide, and disopyramide should generally not be started out of
hospital. An exception can be made for disopyramide in patients
without heart disease who have a normal QT interval. Currently,
the standards for use of dofetilide do not permit out-of-hospital
initiation.
Transtelephonic monitoring or other ECG surveillance
methods can be used to monitor conduction disturbances as
pharmacological antiarrhythmic therapy is initiated in pa-
tients with AF. Specifically, the PR interval (flecainide,
propafenone, sotalol, and amiodarone), QRS duration (fle-
cainide and propafenone), and QT interval (sotalol, amiodarone,
and disopyramide) should be measured. As a general rule,
antiarrhythmic drugs should be started at a relatively low dose
with upward titration as needed, reassessing the ECG as each
dose change is made. The dose of other medication used for rate
control should be reduced approximately 6 weeks after initiation
of amiodarone and stopped if the rate slows excessively. Con-
comitant drug therapies should be monitored closely, and both
the patient and the physician should be alert to possible delete-
rious drug interactions.
5. Recurrence of AF After Cardioversion: Implications
for Drug Treatment
Although it has long been known that most recurrences of
AF occur within the first month after electrical cardioversion,
recent research with internal atrial cardioversion (125) and
day-to-day postconversion studies (126) have established
several patterns of recurrence (Fig. 5). In some cases, there is
complete failure of direct-current countershock to elicit even
a single isolated sinus or ectopic atrial beat, tantamount to a
high atrial defibrillation threshold. In others, AF reappears
within 1 to 2 minutes after a period of sinus rhythm
(127,128). Sometimes recurrence is delayed from 1 day to 2
weeks (126) or more after the shock. Complete shock failure
and immediate recurrences occur in approximately 25% of
patients undergoing electrical cardioversion, and subacute
recurrences occur in about an equal proportion within 2
weeks (127).
Available data suggest that starting pharmacological ther-
apy before electrical cardioversion (Table 5) can enhance
immediate success and suppress early recurrences. As a
corollary, it seems appropriate to establish therapeutic plasma
drug concentrations at the time of cardioversion and for a few
weeks thereafter to optimize the chance of success. After
cardioversion to sinus rhythm, patients receiving drugs that
TABLE 4. Types of Proarrhythmia During Treatment With
Various Antiarrhythmic Drugs for Atrial Fibrillation or Atrial
Flutter According to the Vaughan Williams Classification
A. Ventricular proarrhythmia
c Torsade de pointes (VW type IA and type III drugs)
c Sustained monomorphic ventricular tachycardia (usually VW type IC
drugs)
c Sustained polymorphic ventricular tachycardia/VF without long QT (VW
types IA, IC, and III drugs)
B. Atrial proarrhythmia
c Provocation of recurrence (probably VW types IA, IC, and III drugs)
c Conversion of AF to flutter usually VW type IC drugs)
c Increase of defibrillation threshold (a potential problem with VW type IC
drugs)
C. Abnormalities of conduction or impulse formation
c Acceleration of ventricular rate during AF (VW type IA and type IC drugs)
c Accelerate conduction over accessory pathway (digoxin, intravenous
verapamil or diltiazem)
c Sinus node dysfunction and atrioventricular block (almost all drugs)
VW indicates the Vaughan Williams classification of antiarrhythmic drugs
(95). VF indicates ventricular fibrillation; AF, atrial fibrillation.
Figure 5. Hypothetical illustration of cardioversion failure.Three
types of recurrences after electrical cardioversion of persistent
AF are shown The efficacy of drugs varies in enhancement of
shock conversion and suppression of recurrences ECV indicates
external cardioversion; IRAF, first recurrence of AF after cardio-
version. Modified with permission from Van Gelder et al (129).
2128 Circulation October 23, 2001
 by guest on A
pril 2, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
prolong QT interval should be observed in the hospital for 24
to 48 h to evaluate the effects of heart rate slowing and to
allow prompt intervention in the event torsade de pointes
develops. Pharmacological agents may be started out of
hospital or in hospital immediately before electrical cardio-
version. The risks of pretreatment include the possibility of a
paradoxical increase in the defibrillation threshold, as has
occurred with flecainide (130); accelerated ventricular rate
during loading with type IA or IC drugs in the absence of an
AV nodal blocking agent (118–122,131) and ventricular
proarrhythmia (Table 4).
Pretreatment with pharmacological agents is most appro-
priate in patients who have previously failed to respond to
electrical cardioversion and in those who developed immedi-
ate or subacute recurrence of AF. In patients with late
recurrence and those undergoing initial cardioversion of
persistent AF, pretreatment is optional (Fig. 10 and 11; see
Section IX).
6. Selection of Antiarrhythmic Agents in Patients
With Certain Cardiac Diseases
a. Heart Failure
Patients with congestive HF are particularly prone to the
ventricular proarrhythmic effects of antiarrhythmic drugs.
Randomized trials have demonstrated the safety of amioda-
rone and dofetilide (given separately) in patients with HF
(132,133), and these are the recommended drugs for mainte-
nance of sinus rhythm (Fig. 11; see Section IX).
b. Coronary Artery Disease
In stable patients with CAD, beta-blockers may be considered
first, but their use is supported by only 2 studies (134–135);
data on their efficacy for maintenance of sinus rhythm in
patients with persistent AF after cardioversion are not con-
vincing (134). Sotalol has substantial beta-blocking activity
and can therefore be chosen as the initial antiarrhythmic agent
in AF patients with ischemic heart disease, because it is
associated with less long-term toxicity than amiodarone (Fig.
11; see Section IX). Both sotalol and amiodarone have
reasonable short-term safety profiles, and amiodarone might
be preferred in patients with HF (136–138). Flecainide (139)
and propafenone are not recommended in these situations.
Quinidine, procainamide, and disopyramide are considered
third-line treatment choices in patients with CAD. Given the
results of the DIAMOND-MI trial (Danish Investigations of
Arrhythmias and Mortality on Dofetilide in Myocardial
Infarction), dofetilide may be considered as a second-line
rather than a third-line antiarrhythmic agent, but that study
involved selected post-myocardial infarction patients in
whom the antiarrhythmic benefit balanced the risk of proar-
rhythmic toxicity.
c. Hypertensive Heart Disease
Patients with LVH are at increased risk of developing torsade
de pointes related to early ventricular afterdepolarizations
(140–142). Thus, a drug that does not prolong the QT interval
is preferable as first-line therapy, and in the absence of CAD
or marked ventricular hypertrophy, propafenone and flecain-
ide are reasonable choices (Fig. 11; Section IX). Amiodarone
prolongs the QT interval but carries a very low risk of
ventricular proarrhythmia; its extracardiac toxicity profile
relegates it to second-line therapy in these individuals, but
amiodarone becomes first-line therapy when marked LVH is
present. When amiodarone and sotalol either fail or are
inappropriate, disopyramide, quinidine, or procainamide can
be used as alternatives.
d. WPW Syndrome
Radiofrequency ablation of the accessory pathway is the
preferred therapy for patients with preexcitation syndromes
and AF, but antiarrhythmic drugs might be useful. Digoxin
should be avoided because of the risk of paradoxical accel-
eration of the ventricular rate during AF. Beta-blockers do not
decrease conduction over accessory pathways during preex-
cited periods of AF.
TABLE 5. Pharmacological Treatment Before Cardioversion in Patients With Persistent Atrial Fibrillation: Effects of Various
Antiarrhythmic Drugs on Acute and Subacute Outcome of Transthoracic Direct Current Shock
Enhance Conversion
by DC Shock and
Prevent IRAF*
Suppress SRAF and
Maintenance Therapy Class
Recommendation
Class
Level of
Evidence
Effective Amiodarone
Flecainide
Ibutilide
Propafenone
Propafenone1verapamil
Quinidine
Sotalol
All drugs in recommendation Class I
(except ibutilide) plus beta-blockers
I B
Uncertain/unknown Beta-blockers
Disopyramide
Diltiazem
Dofetilide
Procainamide
Verapamil
Diltiazem
Dofetilide
Verapamil
IIb B
All drugs (except beta-blockers and amiodarone) should be initiated in hospital. IRAF indicates immediate recurrence of atrial fibrillation; SRAF, subacute recurrence
of atrial fibrillation; and DC, direct current.
*Drugs are listed alphabetically within each class of recommendation.
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7. Nonpharmacological Correction of AF
a. Surgical Ablation
Based on mapping studies of animal and human AF, Cox et
al (143–146) developed a surgical procedure (maze opera-
tion) that controls AF in more than 90% of selected patients.
The exact mechanism has not been established conclusively,
but the creation of barriers to conduction within the RA and
LA limits the amount of myocardium available to propagate
reentrant wave fronts, thereby inhibiting sustained AF. Inci-
sions encircling the pulmonary veins can prevent initiation of
AF by isolating potentially arrhythmogenic foci near the
pulmonary veins from the remainder of the atria or by
isolating atrial regions with the shortest refractory periods.
Modifications of the Cox maze operation involve encircling
the pulmonary veins by surgical incisions within the LA and
radial incisions in both atria that join the mitral and tricuspid
valve annuli (147–149).
Surgical operations for AF have been successfully com-
bined with operative correction of a variety of structural
cardiac conditions. In patients with highly symptomatic AF
who require open heart operations for valvular, ischemic, or
congenital heart disease, consideration should be given to
concomitant maze operation for AF or flutter, although this
entails additional risk. The mortality rate of an isolated maze
operation is less than 1%, but mortality is higher when the
procedure is combined with other types of operative repair.
The morbidity associated with the maze operation includes
consequences common to median sternotomy and cardiopul-
monary bypass, as well as a risk of short-term fluid retention
(owing to reduced release of atrial natriuretic peptide),
transient reduction in LA and RA transport function, and
early postoperative atrial tachyarrhythmias. In addition, when
the blood supply to the sinus node is disrupted, sinus node
dysfunction might require permanent pacemaker implanta-
tion. Progressive iterations of these operations have reduced
the risk of this complication to less than 10%.
b. Catheter Ablation
Based on the success of surgical approaches to AF, several
catheter ablation strategies have been designed to produce
similar effects (150–152). Ablation strategies limited to the
RA produce marginal improvement (150), whereas linear
ablation in the LA has been more successful. The recognition
that foci triggering AF often originate within the pulmonary
veins has led to ablation strategies that target this zone or
electrically isolate the pulmonary vein from the LA. Other
sites of arrhythmogenic foci have been found in the superior
vena cava, the RA and LA, and the coronary sinus. Ablation
of these foci eliminates or reduces the frequency of recurrent
AF in more than 60% of patients, but the risk of recurrent AF
after a focal ablation procedure is still 30% to 50% over the
first year and even higher when more than 1 pulmonary vein
is involved. Thus, many patients continue to require antiar-
rhythmic drug therapy after ablative therapy of AF (153).
Potential complications of catheter ablation for AF include
systemic embolism, pulmonary vein stenosis, pericardial
effusion, cardiac tamponade, and phrenic nerve paralysis.
Thus, although these procedures have produced promising
results, they have not yet been widely applied.
Atrial flutter can develop not only as a distinct arrhythmia
but also during antiarrhythmic drug therapy of AF, especially
with type IC agents. Catheter ablation is more effective than
antiarrhythmic drugs for treatment of atrial flutter, reducing
the recurrence rate from 93% to 5% when used as first-line
therapy (37). In addition, the risk of developing AF might
also be lower after catheter ablation of atrial flutter than with
pharmacological therapy (29% vs 60% over the first year).
c. Suppression of AF by Pacing
Although atrium-based pacing is associated with a lower risk
of AF and stroke than ventricle-based pacing for patients
requiring pacemakers for bradyarrhythmias, the use of pacing
as a primary therapy for prevention of recurrent AF has not
been validated.
d. Internal Atrial Cardioverter/Defibrillators
There has been an interest in internal cardioversion of AF for
the past 10 years. Attempts have been made to find shock
waveforms that reduce the energy requirements for cardio-
version, making the shock tolerable to awake patients. One
cardioverter (154) capable of atrial sensing and cardioversion
as well as ventricular sensing and pacing was evaluated in
290 AF patients. The conversion rate to sinus rhythm was
93%. Another device, with dual-chamber sensing, pacing,
and cardioversion/defibrillation capabilities and a maximum
output of 27 J, is a ventricular defibrillator with atrial
cardioversion capabilities. It was designed to treat both atrial
and ventricular arrhythmias with pacing modalities before
delivering low-energy shocks. Potential candidates for atrial
cardioverter/defibrillators, mainly those with infrequent epi-
sodes of poorly tolerated AF, are often suitable for catheter
ablation.
F. Rate Control During AF
1. Pharmacological Approach
An alternative to maintenance of sinus rhythm in patients
with paroxysmal or persistent AF is control of the ventricular
rate. In a recent randomized trial, the therapeutic strategies of
rate versus rhythm control yielded similar clinical results with
respect to symptoms in patients with AF, but exercise
tolerance was better with rhythm control (111). The results of
other studies comparing these 2 strategies are not yet avail-
able (80). The rate is generally considered controlled when
the ventricular response is between 60 and 80 bpm at rest and
between 90 to 115 bpm during moderate exercise (156,157).
Heart rate variability during AF provides additional informa-
tion about the status of the autonomic nervous system, which
might have independent prognostic implications (158–161).
Negative chronotropic therapy of AF is based mainly on
depression of conduction across the AV node. Sinus brady-
cardia and heart block occur in some patients with paroxys-
mal AF, particularly the elderly, as an unwanted effect of
pharmacological intervention with beta-blockers, digitalis
glycosides, or calcium channel antagonists. Table 6 outlines
agents that may be administered to control the ventricular
response to AF in an emergency setting. Table 7 outlines
drugs that block AV nodal conduction; these drugs can be
used to achieve rate control both at rest and during exercise or
other types of cardiovascular stress. A combination of drugs
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is often necessary to achieve rate control in AF patients in the
acute and chronic settings. Therapy often requires careful
dose titration, and some patients develop symptomatic bra-
dycardia that requires permanent pacing.
2. Nonpharmacological Regulation of AV Nodal
Conduction and Pacing
Because ventricular pacing prolongs the AV nodal refrac-
tory period as a result of concealed retrograde penetration, it
eliminates ventricular cycles longer than the pacing cycle
length and reduces the number of short ventricular cycles
related to rapid AV conduction during AF. As a result,
ventricular pacing can be used as a strategy to reduce the
irregularity of the ventricular rhythm (162). This modality
can be useful for patients with marked variability in ventric-
ular rates and for those who develop resting bradycardia
during treatment with medications prescribed to control rapid
ventricular rates with exertion. The precise role of pacemaker
therapy to regulate the ventricular rate in patients with AF,
however, remains controversial.
3. Nonpharmacological/AV Nodal Ablation
AV nodal ablation and permanent pacemaker implantation
are highly effective means of improving symptoms in patients
TABLE 6. Intravenous Pharmacological Agents for Heart Rate Control in Patients With Atrial Fibrillation
Drug* Loading Dose Onset Maintenance Dose Major Side Effects
Class
Recommendation
Diltiazem 0.25 mg/kg IV over 2 min 2–7 min 5–15 mg per hour infusion Hypotension, heart block,
HF
I†
Esmolol‡ 0.5 mg/kg over 1 min 5 min 0.05–0.2 mgkg21min21 Hypotension, heart block,
bradycardia, asthma, HF
I
Metoprolol‡ 2.5–5 mg IV bolus over 2 min; up
to 3 doses
5 min NA Hypotension, heart block,
bradycardia, asthma, HF
I†
Propranolol‡ 0.15 mg/kg IV 5 min NA Hypotension, heart block,
bradycardia, asthma, HF
I†
Verapamil 0.075–0.15 mg/kg IV over 2 min 3–5 min NA Hypotension, heart block,
HF
I†
Digoxin 0.25 mg IV each 2 h, up to 1.5 mg 2 h 0.125–0.25 mg daily Digitalis toxicity, heart
block, bradycardia
IIb**
HF indicates heart failure.
*Drugs are listed alphabetically within each class of recommendation.
**Type I in congestive HF.
†Type IIb in congestive HF.
‡Only representative members of the type of beta-adrenergic antagonist drugs are included in the table, but other, similar agents could be used for this indication
in appropriate doses.
TABLE 7. Recommendations for Use of Orally Administered Pharmacological Agents for Heart Rate Control in Patients With Atrial
Fibrillation
Drug* Loading Dose Onset Usual Maintenance Dose** Major Side Effects Recommendation
Digoxin 0.25 mg PO each 2 h; up
to 1.5 mg
2 h 0.125–0.375 mg daily Digitalis toxicity, heart block, bradycardia I
Diltiazem NA 2–4 h 120–360 mg daily in divided
doses; slow release
available
Hypotension, heart block, HF I
Metoprolol† NA 4–6 h 25–100 mg BID Hypotension, heart block, bradycardia,
asthma, HF
I
Propranolol† NA 60–90 min 80–240 mg daily in divided
doses
Hypotension, heart block, bradycardia,
asthma, HF
I
Verapamil NA 1–2 h 120–360 mg daily in divided
doses; slow release
available
Hypotension, heart block, HF, digoxin
interaction
I
Amiodarone 800 mg daily for 1 wk
600 mg daily for 1 wk
400 mg daily for 4–6 wk
1–3 wk 200 mg daily Pulmonary toxicity, skin discoloration,
hypothyroidism, corneal deposits,
optic neuropathy, warfarin interaction,
proarrhythmia
IIb
HF indicates heart failure; PO, by mouth; NA, not applicable; HF, heart failure; and BID, twice a day.
*Drugs are listed alphabetically within each class of recommendation.
**Recommended maintenance dosages are the usual ones necessary, but higher doses may be appropriate in some patients.
†The table includes representative members of the type of beta-blocker drugs, but other, similar agents could be used for this indication in appropriate doses.
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with AF who experience symptoms related to a rapid ven-
tricular rate during AF that cannot be adequately controlled
with antiarrhythmic or negative chronotropic medications
(83,84,86,163). AV nodal ablation is especially useful when
an excessive ventricular rate induces a tachycardia-mediated
decline in ventricular systolic function despite appropriate
medical therapy.
The limitations of AV nodal ablation include the persistent
need for anticoagulation, loss of AV synchrony, and lifelong
pacemaker dependency. There is a small but real risk of
sudden death, largely due to torsade de pointes (164). In
addition, ablation of the AV conduction system might pre-
clude or limit the later use of newer nonpharmacological
treatments. Patients with impaired diastolic ventricular compli-
ance who are most dependent on AV synchrony for maintenance
of cardiac output (such as HCM or restrictive cardiomyopathies)
might experience persistent symptoms after AV nodal ablation
and permanent pacemaker implantation. Thus, patients must be
counseled regarding each of these considerations before pro-
ceeding with this irreversible treatment.
The use of catheter ablation to modify AV nodal conduc-
tion by eliminating posterior atrial inputs to the AV node has
been reported to decrease the ventricular rate during AF and
to improve cardiac symptoms without requiring pacemaker
implantation (165,166). This technique has several limita-
tions, including the inadvertent induction of complete AV
block and a relatively high risk of increasing ventricular rate
over the first 6 months after ablation. Thus, AV nodal
modification without pacemaker implantation is only rarely
used for patients with rapid ventricular rates during AF.
G. Preventing Thromboembolism
1. Risk Stratification
a. Epidemiological Data
The rate of stroke in patients with AF is related to
coexistent cardiovascular disease (4,19,73,74). In a small,
retrospective, population-based study in Olmsted County,
Minnesota, over 3 decades, the 15-year cumulative stroke rate
in people with lone AF (defined as those younger than age 60
years with no clinical history or echocardiographic signs of
cardiopulmonary disease) was 1.3% per year (4). Conversely,
in the Framingham Study, the age-adjusted stroke rate over a
mean follow-up period of 11 years was 28.2% in those with
lone AF, which was more liberally defined to include patients
with a history of hypertension or cardiomegaly on chest
roentgenography; by comparison, the rate was 6.8% in
normal controls. In the SPAF study, the annualized rate of
ischemic stroke was similar in those with recurrent (3.2%)
and permanent (3.3%) AF (167). Those with prior stroke or
transient ischemic attack have a rate of subsequent stroke of
10% to 12% per year despite aspirin use and benefit substan-
tially from treatment with adjusted-dose oral anticoagulation
(168,169). In addition to prior thromboembolism, indepen-
dent risk factors for ischemic stroke in nonvalvular AF
include HF, hypertension, increasing age, and diabetes mel-
litus (19,73,170–172). Female sex, blood pressure greater
than 160 mmHg, and LV dysfunction have each been linked
to stroke (75,170,173). The relative risk for ischemic stroke
associated with specific clinical features is given in Table 8.
Nearly half of AF-associated strokes occur in patients greater
than 75 years old, and AF is the most frequent cause of
disabling stroke in elderly women (9,171,173). Older people
are at increased risk for anticoagulant-related bleeding (174)
and are therefore less likely to be treated with oral anticoag-
ulation, even in situations for which it has been proven
efficacious (175). Special consideration of the elderly is
therefore warranted for effective stroke prophylaxis (171).
Patients with AF related to thyrotoxicosis, which is often
associated with congestive HF, are also at increased risk for
stroke (176–178), although the underlying mechanism is not
clear (52,179,180). AF is a frequent complication of HCM
(181), and such patients have an incidence of stroke and
systemic embolism amounting to 2.4% to 7.1% per year
(182–185).
b. Role of Echocardiography in Risk Stratification
Transthoracic Echocardiography: In a meta-analysis of 3
randomized trials of antithrombotic therapy, moderate to
severe LV dysfunction was the only independent echocardio-
graphic predictor of stroke in patients with AF when clinical
features were also considered (186). The diameter of the LA
was a less useful predictor of ischemic events (186). Trans-
thoracic Echocardiography TEE is the most sensitive and
specific imaging technique for detection of LA and LA
appendage (LAA) thrombus, far surpassing transthoracic
echocardiography (52). This modality also permits superior
evaluation for other causes of cardiogenic embolism (187)
and superiority in measuring LAA function (188). Several
TEE features have been associated with thromboembolism,
including such LA/LAA abnormalities as thrombus, reduced
flow velocity, and spontaneous echo contrast, as well as
complex atheromatous plaques in the aorta (70,189).
Detection of LA/LAA thrombus stands as a contraindica-
tion to elective cardioversion of AF. The absence of detect-
able thrombus does not preclude thromboembolism after
cardioversion if patients do not receive anticoagulation ther-
apy (190,191). A TEE-guided strategy for elective cardiover-
sion of AF has been reported to result in comparable
outcomes for thromboembolism and death compared with
conventional anticoagulation for 3 weeks before and 4 weeks
after cardioversion (192). Hence, transthoracic echocardiog-
TABLE 8. Risk Factors for Ischemic Stroke and Systemic
Embolism in Patients With Nonvalvular Atrial Fibrillation
Risk Factors (Control Groups)
Relative
Risk
Previous stroke or TIA 2.5
History of hypertension 1.6
Congestive heart failure 1.4
Advanced age (continuous, per decade) 1.4
Diabetes mellitus 1.7
Coronary artery disease 1.5
TIA indicates transient ischemic attack. Relative risk refers to comparison
with atrial fibrillation patients without these risk factors. As a group, patients
with nonvalvular atrial fibrillation have about a 6-fold increased risk of
thromboembolism compared with patients in normal sinus rhythm. Data from
collaborative analysis of five primary prevention trials (75).
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raphy is valuable for defining the origin of AF (eg, to detect
rheumatic mitral valve disease or HCM), and TEE can
provide additional information for stratifying thromboem-
bolic risk. Three clinical schemes have been proposed re-
cently to stratify the risk of ischemic stroke in AF patients
that are directly or indirectly based on analyses of prospec-
tively monitored cohorts of participants in clinical trials in
which antithrombotic therapy was controlled (172,186,193).
One set of criteria is based on multivariate pooled analysis of
1593 participants assigned to the control or placebo groups of
5 randomized primary prevention trials in which 106 isch-
emic strokes occurred over a mean follow-up of 1.4 years
(19). This scheme divides patients into 2 strata, distinguishing
low-risk patients from those at intermediate or high risk.
Echocardiographic features were not considered initially, but
subsequent analysis of 3 of these trials identified abnormal
LV systolic function as an independent predictor of stroke
(186). The SPAF study criteria were based on multivariate
analysis of 854 participants assigned aspirin in the SPAF-I
and -II clinical trials who were followed up for a mean of 2.3
years, during which 68 ischemic strokes were observed. A
third set of criteria was developed by expert consensus (193)
based on consideration of the 2 foregoing schemes and other
available data to classify patients into low-, intermediate-,
and high-risk groups (Table 9).
c. Therapeutic Implications
The risk of thromboembolism for patients with chronic atrial
flutter is generally estimated as higher than for patients with
sinus rhythm but less than for those with persistent or
permanent AF. Biblo et al. (196) recently reviewed 8 years of
retrospective data on 749,988 hospitalized older patients,
including 17,413 with atrial flutter and 337,428 with AF. The
overall stroke risk ratio for patients with atrial flutter was 1.4
compared with the control group; for patients with AF, the
relative risk was 1.6. As a chronic arrhythmia, atrial flutter is
uncommon, and the risk of thromboembolism is not as well
established as it is for AF. Until more robust data become
available, and although the overall thromboembolic risk
associated with atrial flutter can be lower than with AF, it
seems prudent to estimate risk by use of similar stratification
criteria.
2. Antithrombotic Strategies for Prevention of Ischemic
Stroke and Systemic Embolism
Five large randomized trials published between 1989 and
1992 evaluated oral anticoagulation, and 2 tested aspirin for
primary prevention of thromboembolism in patients with
nonvalvular AF (24,197–199). A sixth trial focused on
secondary prevention among patients who had survived
nondisabling stroke or transient cerebral ischemic attack
(169). Meta-analysis according to the principle of intention to
treat showed that adjusted-dose oral anticoagulation is highly
efficacious for prevention of all stroke (both ischemic and
hemorrhagic), with a risk reduction of 61% (95% CI 47% to
71%) vs placebo (200) (Fig. 6). This reduction was similar for
both primary and secondary prevention. The duration of
follow-up in these trials was generally between 1 and 2 years;
the longest was 2.2 years, whereas in clinical practice, the
need for antithrombotic therapy typically extends over much
longer periods.
Patient age and the intensity of anticoagulation are the
most powerful predictors of major bleeding (201–204). Trial
participants, at an average age of 69 years, were carefully
selected and managed. It is thus unclear whether the relatively
low rates of major hemorrhage also apply to AF patients in
clinical practice, who have a mean age of approximately 75
years and whose anticoagulation therapy is less closely
regulated (205,206).
The target intensity of anticoagulation involves a balance
between prevention of ischemic stroke and avoidance of
hemorrhagic complications. It is important to target the
lowest adequate intensity of anticoagulation to minimize the
risk of bleeding, particularly for elderly AF patients. Maxi-
TABLE 9. Published Risk-Stratification Schemes for Primary* Prevention of Thromboembolism in Patients With Nonvalvular
Atrial Fibrillation
Source High Risk Intermediate Risk Low Risk
Atrial Fibrillation Investigators (194)† Age greater than or equal to 65 years
History of hypertension
Coronary artery disease
Diabetes
Age less than 65 years
No high-risk features
American College of Chest Physicians
(193)
Age greater than 75 years
History of hypertension
Left ventricular dysfunction‡
More than 1 intermediate risk factor
Age 65–75 years
Diabetes
Coronary artery
disease
Thyrotoxicosis
Age less than 65 years
No risk factors
Stroke Prevention in Atrial Fibrillation (186) Women greater than 75 years
Systolic BP greater than 160 mm Hg
Left ventricular dysfunction†
History of hypertension
No high-risk features
No high-risk features
No history of hypertension
BP indicates blood pressure. Patients are classified on the basis of the presence or absence of any risk factor.
Adapted with permission from Am J Med, Vol. 109, Pearce et al., Assessment of these schemes for stratifying stroke risk in patients with nonvalvular atrial
fibrillation, pp. 45–51, © 2000, with permission, from Excerpta Medica, Inc. (195).
*Patients with AF and prior thromboembolism are at high risk of stroke, and anticoagulation is indicated for secondary prevention in such cases.
†Did not distinguish high-risk from intermediate-risk patients.
‡Left ventricular dysfunction refers to moderate to severe wall motion abnormality assessed globally by 2-dimensional echocardiography, reduced ejection fraction,
fractional shortening less than 0.25 by M-mode echocardiography, or clinical heart failure.
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mum protection against ischemic stroke in AF is probably
achieved with an international normalized ratio (INR) of 2 to
3 (168,207,208), whereas an INR range of 1.6 to 2.5 appears
to be associated with incomplete efficacy, estimated at
approximately 80% of that achieved with higher intensity
anticoagulation (Fig. 7) (207,209).
In patients with AF who do not have mechanical valves, it
is the consensus of the writing group that anticoagulation can
be interrupted for a period of up to 1 week for procedures that
carry a risk of bleeding, without substituting heparin. In
high-risk patients, or when a series of procedures requires
interruption for a period longer than 1 week, unfractionated or
low-molecular-weight heparin can be administered intrave-
nously or subcutaneously, respectively.
Low-molecular-weight heparins have several pharmaco-
logical advantages over unfractionated heparin. These include
a longer half-life, more predictable bioavailability (greater
than 90% after subcutaneous injection), predictable clearance
(enabling once- or twice-daily subcutaneous administration),
and predictable antithrombotic response based on body
weight, which permits fixed-dose treatment without labora-
tory monitoring except under special circumstances, such as
obesity, renal insufficiency, or pregnancy (210). Low-
molecular-weight heparins carry a lower risk of heparin-
induced thrombocytopenia than unfractionated heparin (211).
Self-administration of low-molecular-weight heparins out of
hospital is a promising approach that can result in cost
savings in conjunction with elective cardioversion (212).
Aspirin offers only modest protection against stroke for
patients with AF (Fig. 8). The effect is less consistent than
that of oral anticoagulation (200,213). Aspirin might be more
efficacious for AF patients with hypertension or diabetes
(213,214) and for reducing noncardioembolic versus cardio-
embolic ischemic strokes (49). Cardioembolic strokes are, on
average, more disabling than noncardioembolic strokes (69).
3. Conversion to Sinus Rhythm and Thromboembolism
Randomized studies of antithrombotic therapy are lacking
for patients undergoing cardioversion of AF or atrial flutter,
but the risk of thromboembolism was between 1% and 5% in
case-control series (102,215). There is no solid clinical
evidence that cardioversion of AF followed by prolonged
maintenance of sinus rhythm effectively reduces thromboem-
bolism. Patients in whom LAA thrombus is identified by TEE
appear to be at high risk of thromboembolism after cardio-
version of AF or flutter, and they should be treated with
anticoagulation for at least 3 to 4 weeks before and after
either pharmacological or electrical cardioversion.
In a multicenter study (192), 1222 patients with either AF
persisting longer than 2 days or atrial flutter and previous AF
were randomized to a TEE-guided or conventional strategy.
One group received anticoagulation with heparin just before
Figure 6. Antithrombotic therapy for prevention of stroke (isch-
emic and hemorrhagic) in patients with nonvalvular AF:
adjusted-dose warfarin compared with placebo. Adapted with
permission from Hart et al. (170,200) Ann Intern Med
1999;131:492–501. (The American College of Physicians–Ameri-
can Society of Internal Medicine is not responsible for the accu-
racy of the translation.)
Figure 7. Adjusted odds ratios for ischemic stroke and intracranial bleeding in relation to intensity of anticoagulation in randomized
trials of antithrombotic therapy for patients with AF. The data are from Hylek et al (203,207).
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and with warfarin for 4 weeks after cardioversion. When
thrombus was identified, cardioversion was postponed, and
warfarin was administered for 3 weeks before TEE was
repeated. The other group received anticoagulant therapy for
3 weeks before and 4 weeks after cardioversion. Both
approaches were associated with a comparably low risk of
stroke (0.8% with the TEE-guided approach and 0.5% with
the conventional approach) after 8 weeks of follow-up. The
risk of major bleeding did not differ significantly. There were
no differences in the proportion of subjects in whom sinus
rhythm was successfully restored. Thus, the clinical benefit of
the TEE approach was limited to saving time before cardio-
version.
Conversion of AF to sinus rhythm results in transient me-
chanical dysfunction of the LA and LAA (190), known as
“stunning.” This occurs after spontaneous, pharmacological
(216,217), or electrical (217–219) conversion of AF and after
radiofrequency catheter ablation of atrial flutter (220). The loss
of atrial function can be associated with spontaneous echo
contrast (190). Recovery of mechanical function can be delayed
for several weeks, depending in part on the duration of AF
before restoration of sinus rhythm (221–223). This could explain
why some patients with no demonstrable LA thrombus on TEE
before cardioversion subsequently experience thromboembolic
events (191). Presumably, thrombus forms during the period of
stunning and is expelled after the return of mechanical function,
which explains the clustering of thromboembolic events in the
first 10 days after cardioversion (224).
Anticoagulation is recommended for 3 to 4 weeks before
and after cardioversion for patients with AF of unknown
duration or that has lasted more than 48 h. Although LA
thrombus and systemic embolism have been documented in
patients with AF of shorter duration, the need for anticoagu-
lation in such patients is less clear. When acute AF produces
hemodynamic instability, immediate cardioversion should
not be delayed, but intravenous heparin or low-molecular-
weight heparin should be administered first. Protection
against late embolism might require continuation of anti-
coagulation; the duration of anticoagulation after the
procedure depends on the likelihood that AF will recur and
on the patient’s intrinsic risk of thromboembolism.
IX. Proposed Management Strategies
A. Overview of Algorithms for Management of
Patients With AF
Management of patients with AF requires knowledge of its
pattern of presentation (paroxysmal, persistent, or permanent)
and decisions about restoration and maintenance of sinus
rhythm, control of the ventricular rate, and anticoagulation.
These issues are addressed in the various management algo-
rithms for each presentation of AF.
1. Newly Discovered or First Episode of AF (Fig. 9)
It is not always clear whether the initial presentation of AF
is actually the patient’s first episode, particularly in those
with minimal or no symptoms of the dysrhythmia, so both are
considered together. In patients who have self-limited epi-
sodes of paroxysmal AF, antiarrhythmic drugs to prevent
recurrence are usually unnecessary, unless AF is associated
with severe symptoms related to hypotension, myocardial
ischemia, or HF. Whether these individuals require long-term
or even short-term anticoagulation is not clear, and the
decision must be individualized for each patient based on the
intrinsic risk of thromboembolism.
In patients with persistent AF, one option is to accept
progression to permanent AF, with attention to antithrom-
botic therapy and control of the ventricular rate. Although it
might seem reasonable to make at least 1 attempt to restore
sinus rhythm, this is not in the best interest of all patients. An
example is the older man without risk factors for thrombo-
embolism in whom asymptomatic AF is discovered on
routine examination and control of the ventricular rate is
Figure 8. Antithrombotic therapy for prevention of stroke (ischemic and hemorrhagic) in patients with nonvalvular AF: warfarin com-
pared with aspirin and aspirin compared with placebo. Adapted with permission from Hart et al. (170,200) Ann Intern Med
1999;131:492–501. (The American College of Physicians–American Society of Internal Medicine is not responsible for the accuracy of
the translation.)
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readily achieved. Here, the potential toxicity of antiarrhyth-
mic drugs might outweigh the benefit of restoration of sinus
rhythm. If the decision is made to attempt to restore and
maintain sinus rhythm, anticoagulation and rate control are
important before cardioversion. Although long-term antiar-
rhythmic therapy might not be needed to prevent recurrent
AF after cardioversion, short-term therapy might be benefi-
cial. In patients with AF of more than 3 months’ duration,
early recurrence is common after cardioversion. Antiarrhyth-
mic medication can be initiated before cardioversion (after
adequate anticoagulation) in such cases to reduce the likeli-
hood of recurrence, and the duration of drug therapy would be
brief (eg, 1 month).
2. Recurrent Paroxysmal AF (Fig. 10 and 11)
In patients who experience brief or minimally symptomatic
recurrences of paroxysmal AF, it is reasonable to avoid
antiarrhythmic drugs, but troublesome symptoms generally
call for suppressive antiarrhythmic therapy. Rate control and
prevention of thromboembolism are appropriate in both
situations. In any given patient, several different antiarrhyth-
mic drugs might be effective, and the initial selection is thus
based mainly on safety. For individuals with no or minimal
structural heart disease, flecainide, propafenone, and sotalol
are recommended as initial antiarrhythmic therapy because
they are generally well tolerated and are essentially devoid of
extracardiac organ toxicity. When one or another of these
drugs is ineffective or is associated with side effects, then
second or third line choices include amiodarone, disopyr-
amide, procainamide, and quinidine, which have greater
potential for adverse reactions. A nonpharmacological ap-
proach is appropriate for some patients, and this should be
considered before amiodarone therapy is begun. Occasion-
ally, a consistent initiating factor can be found. Disopyramide
or flecainide may be used in cases of vagally mediated AF,
whereas beta-blockers or sotalol is suggested as the initial
agent for adrenergically induced AF.
Many patients with organic heart disease can be broadly
categorized into those with HF, CAD, or hypertension, although
other types of heart disease can also be associated with AF. For
patients with HF, safety data support the selection of amiodarone
or dofetilide to maintain sinus rhythm. Patients with ischemic
heart disease often require beta-blocker medication. Then so-
talol, a drug with both beta-blocking activity and primary
antiarrhythmic efficacy, is considered first unless the patient has
HF. Amiodarone and dofetilide are considered secondary agents
in this situation. The clinician may consider disopyramide,
procainamide, or quinidine on an individual basis. In patients
with hypertension without LVH, drugs such as flecainide and
propafenone, which do not prolong repolarization and the QT
interval, might offer a safety advantage and are recommended
first. If these agents either prove ineffective or produce side
effects, then amiodarone, dofetilide, and sotalol represent appro-
priate secondary choices. Disopyramide, procainamide, and
quinidine are considered third-line agents in this situation.
Hypertrophied myocardium is prone to proarrhythmic toxicity
and development of the torsade de pointes type of ventricular
tachycardia. Amiodarone is suggested as first-line therapy in
patients with LVH (wall thickness greater than or equal to
Figure 9. Pharmacological management of patients with newly discovered AF. AF indicates atrial fibrillation; HF, heart failure.
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1.4 cm) on the basis of its relative safety compared with several
other agents. Because neither ECG nor echocardiography invari-
ably detects LVH as defined by measurement of myocardial
mass, clinicians face a conundrum. The selection of antiarrhyth-
mic drugs for patients with a history of hypertension is com-
pounded by the dearth of prospective controlled trials comparing
the safety and efficacy of drug therapy for AF.
The scarcity of data from randomized trials of antiarrhyth-
mic medications for treatment of patients with AF applies
generally to all patient groups. Accordingly, the drug-
selection algorithm presented here has been developed as a
consensus of experts and is particularly subject to revision as
additional evidence emerges in this field (Fig. 10).
3. Recurrent Persistent AF (Fig. 11 and 12)
Patients with minimal symptoms who have undergone at
least 1 attempt to restore sinus rhythm can remain in AF with
therapy for rate control and prevention of thromboembolism.
Alternatively, those with symptoms favoring sinus rhythm
should be treated with an antiarrhythmic agent (in addition to
medications for rate control and anticoagulation) before cardio-
version. The selection of an antiarrhythmic drug should be based
on the same algorithm used for patients with recurrent paroxys-
mal AF.
4. Permanent AF (Fig. 12)
Permanent AF is the designation given to cases in which
sinus rhythm cannot be sustained after cardioversion of AF or
when the patient and physician have decided to allow AF to
continue without further efforts to restore sinus rhythm. It is
important to maintain control of the ventricular rate and to
use antithrombotic therapy, as outlined elsewhere in this
document, for all patients in this category.
B. Recommendations for Management of Patients
With AF
Recommendations are evidence based and are derived pri-
marily from published data. The weight of evidence was
ranked highest (A) when the data were derived from multiple
randomized clinical trials and intermediate (B) when the data
were derived from a limited number of randomized trials,
nonrandomized studies, or observational registries. A lower
rank (C) was given when the primary basis for the recom-
mendation was expert consensus.
Recommendations follow the format of previous ACC/
AHA guidelines for classifying indications, summarizing
both the evidence and expert opinion:
Class I: Conditions for which there is evidence for
and/or general agreement that the procedure
or treatment is useful and effective.
Class II: Conditions for which there is conflicting evi-
dence and/or a divergence of opinion about
the usefulness/efficacy of a procedure or treat-
ment.
Class IIa: The weight of evidence or opinion
is in favor of the procedure or treatment.
Class IIb: Usefulness/efficacy is less well es-
tablished by evidence or opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure or
treatment is not useful/effective and in some
cases can be harmful.
The reader is referred to the full-text guidelines available on
the ACC (www.acc.org), AHA (www.americanheart.org), ESC
(www.escardio.org), and NASPE (www.naspe.org) World Wide
Web sites and published in the European Heart Journal in
mid-October 2001 for a complete description of the rationale and
evidence supporting these recommendations.
Recommendations for Pharmacological and
Electrical Cardioversion of AF
Class I
1. Immediate electrical cardioversion in patients with
paroxysmal AF and a rapid ventricular response
who have ECG evidence of acute MI or symptomatic
hypotension, angina, or HF that does not respond
promptly to pharmacological measures. (Level of
Evidence: C)
2. Cardioversion in patients without hemodynamic in-
stability when symptoms of AF are unacceptable.
(Level of Evidence: C)
Class IIa
1. Pharmacological or electrical cardioversion to accel-
erate restoration of sinus rhythm in patients with a
first-detected episode of AF. (Level of Evidence: C)
(See Tables 10 through 12 for recommended drugs.)
2. Electrical cardioversion in patients with persistent
AF when early recurrence is unlikely. (Level of
Evidence: C)
3. Repeated cardioversion followed by prophylactic
drug therapy in patients who relapse to AF without
antiarrhythmic medication after successful cardio-
version. (Level of Evidence: C)
Class IIb
1. Pharmacological agents for cardioversion to sinus
rhythm in patients with persistent AF. (Level of
Evidence: C) (See Tables 10 through 12 for recom-
mended drugs.)
Figure 10. Pharmacological management of patients with recur-
rent paroxysmal AF. *See Figure 11 for suggested drugs.
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2. Out-of-hospital administration of pharmacological
agents for cardioversion of first-detected, paroxysmal,
or persistent AF in patients without heart disease or
when the safety of the drug in the particular patient
has been verified. (Level of Evidence: C) (See Table 12.)
Class III
1. Electrical cardioversion in patients who display
spontaneous alternation between AF and sinus
rhythm over short periods of time. (Level of Evi-
dence: C)
2. Additional cardioversion in patients with short
periods of sinus rhythm who relapse to AF despite
multiple cardioversion procedures and prophylac-
tic antiarrhythmic drug treatment. (Level of Evi-
dence: C)
Recommendations for Pharmacological
Therapy to Maintain Sinus Rhythm
(See Table 3)
Pharmacological management strategies or algorithms to
maintain sinus rhythm in patients with AF (Figs. 9, 10, 11,
12) are based on available evidence and extrapolated from
experience with these agents in other situations.
Class I
1. Base selection of pharmacological therapy to main-
tain sinus rhythm in patients with disabling or
otherwise troublesome symptoms during AF pre-
dominantly on safety. (Level of Evidence: B)
2. Treat precipitating or reversible causes of AF before
initiating antiarrhythmic drug therapy. (Level of
Evidence: C)
Class IIa
1. Administer pharmacological therapy to maintain
sinus rhythm to prevent progression of tachycardia-
induced cardiomyopathy due to AF. (Level of Evi-
dence: C)
2. Infrequent and well-tolerated recurrence of AF may
in some cases be deemed a successful outcome of
antiarrhythmic drug therapy. (Level of Evidence: C)
Figure 11. Antiarrhythmic drug therapy to maintain sinus rhythm in patients with recurrent paroxysmal or persistent atrial fibrillation.
Drugs are listed alphabetically and not in order of suggested use. *For adrenergic atrial fibrillation, beta-blockers or sotalol are the initial
drugs of choice. †Consider nonpharmacological options to maintain sinus rhythm if drug failure occurs. HF indicates heart failure; CAD,
coronary artery disease; and LVH, left ventricular hypertrophy.
Figure 12. Pharmacological management of patients with recur-
rent persistent or permanent AF. *See Fig. 11. Initiate drug ther-
apy before cardioversion to reduce the likelihood of early recur-
rence of AF.
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3. Outpatient initiation of antiarrhythmic drug treat-
ment is appropriate in selected patients. (Level of
Evidence: C)
Class IIb
1. Administer pharmacological therapy to maintain
sinus rhythm in asymptomatic patients to prevent
atrial remodeling. (Level of Evidence: C)
2. Administer pharmacological therapy to maintain
sinus rhythm to prevent thromboembolism or HF in
selected patients. (Level of Evidence: C)
3. Administer combinations of antiarrhythmic agents
to maintain sinus rhythm when single-drug therapy
fails. (Level of Evidence: C)
Class III
1. Use of a particular pharmacological agent to main-
tain sinus rhythm in patients with well-defined
proarrhythmia risk factors for that agent. (Level of
Evidence: A)
2. Use of pharmacological therapy to maintain sinus
rhythm in patients with advanced sinus node or AV
node dysfunction in the absence of a functioning
electronic cardiac pacemaker. (Level of Evidence: C)
Recommendations for Heart Rate Control in
Patients With AF (See Tables 6, 7, and 13)
Class I
1. Measure heart rate response both at rest and during
exercise in patients with persistent or permanent AF
and control the rate with pharmacological agents
(using a beta-blocker or calcium channel antagonist
in most cases) to the physiological range. (Level of
Evidence: C)
2. Administer intravenous beta-blockers or calcium
channel antagonists (verapamil, diltiazem) in the
acute setting to slow the ventricular response to AF
in the absence of conduction over an accessory
pathway, exercising caution in patients with hypo-
tension or HF. (Level of Evidence: B)
3. Perform immediate electrical cardioversion in pa-
tients with acute paroxysmal AF and a rapid ventric-
ular response associated with acute myocardial infarc-
tion, symptomatic hypotension, angina, or cardiac
TABLE 10. Recommendations for Pharmacological Cardioversion of AF Less Than or Equal to 7 Days Duration**
Drug*
Route of
Administration
Type of
Recommendation
Level of
Evidence References
Agents with proven efficacy
Dofetilide Oral I A 133, 225–229
Flecainide Oral or intravenous I A 88–90, 92, 230–235
Ibutilide Intravenous I A 236–241
Propafenone Oral or intravenous I A 90, 93, 94, 230, 233, 235, 242–252
Amiodarone Oral or intravenous IIa A 92, 96, 124, 234, 251, 253–260
Quinidine Oral IIb B 88, 90, 91, 93, 242, 256, 257, 261, 262
Less effective or incompletely studied agents
Procainamide Intravenous IIb C 237, 238, 263
Digoxin Oral or intravenous III A 93, 233, 244, 259, 264–267
Sotalol Oral or intravenous III A 239, 261, 262, 266, 268
*Drugs are listed alphabetically within each category of recommendation and level of evidence.
**The doses of medications used in these studies may not be the same as those recommended by the manufacturers.
TABLE 11. Recommendations for Pharmacological Cardioversion of AF More Than 7 Days Duration**
Drug*
Route of
Administration
Type of
Recommendation
Level of
Evidence References
Agents proven effective
Dofetilide Oral I A 133, 225–229
Amiodarone Oral or intravenous IIa A 92, 96, 124, 234, 251, 253–260
Ibutilide Intravenous IIa A 236–241
Flecainide Oral IIb B 88–90, 92, 230–235
Propafenone Oral or intravenous IIb B 90, 93, 94, 230, 233, 235, 242–252
Quinidine Oral IIb B 88, 90, 91, 93, 242, 256, 257, 261, 262
Less effective or incompletely studied agents
Procainamide Intravenous IIb C 237, 238, 263
Sotalol Oral or intravenous III A 239, 261, 262, 266, 268
Digoxin Oral or intravenous III C 93, 233, 244, 259, 264–267
*Drugs are listed alphabetically within each category of recommendation and level of evidence.
**The doses of medications used in these studies may not be the same as those recommended in Table 3 or by the manufacturers.
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failure that does not respond promptly to pharmaco-
logical measures. (Level of Evidence: C)
Class IIa
1. Administer a combination of digoxin and a beta-
blocker or calcium channel antagonist to control the
heart rate at rest and during exercise in patients
with AF. The choice of medication should be indi-
vidualized and the dose modulated to avoid brady-
cardia. (Level of Evidence: C)
2. Employ nonpharmacological therapy to control
heart rate when pharmacological therapy is insuffi-
cient. (Level of Evidence: C)
Class IIb
1. Administer digoxin as the sole agent to control heart
rate at rest in patients with persistent AF. (Level of
Evidence: B)
2. Administer intravenous quinidine, procainamide, di-
sopyramide, ibutilide, or amiodarone to hemody-
namically stable patients with AF involving conduc-
tion over an accessory pathway. (Level of Evidence:
B)
3. Immediate cardioversion is required when very
rapid tachycardias or hemodynamic instability oc-
curs in patients with AF involving conduction over
an accessory pathway. (Level of Evidence: B)
Class III
1. Administer digitalis as the sole agent to control a
rapid rate of ventricular response to AF in patients
with paroxysmal AF. (Level of Evidence: B)
2. Catheter ablation without prior medical therapy to
control AF. (Level of Evidence: C)
Recommendations for Antithrombotic
Therapy in Patients With AF (see Table 14)
Class I
1. Administer antithrombotic therapy (oral anticoagu-
lation or aspirin) to all patients with AF, except
those with lone AF, to prevent thromboembolism.
(Level of Evidence: A)
2. Individualize the selection of the antithrombotic
agent based on assessment of the absolute risks of
stroke and bleeding and the relative risk and
benefit for a particular patient. (Level of Evidence:
A)
3. Chronic oral anticoagulant therapy in a dose ad-
justed to achieve a target intensity of INR 2 to 3 in
patients at high risk of stroke, unless contraindi-
cated. (Level of Evidence: A)
a. The need for anticoagulation should be reeval-
uated at regular intervals. (Level of Evidence:
A)
b. INR should be determined at least weekly
during the initiation of oral anticoagulation
therapy and monthly when the patient is stable.
(Level of Evidence: A)
4. Aspirin in a dose of 325 mg daily as an alternative in
low-risk patients or in those with certain contrain-
dications to oral anticoagulation. (Level of Evidence:
A)
5. Oral anticoagulation for patients with AF who have
rheumatic mitral valve disease or prosthetic heart
valves (mechanical or tissue valves). (Level of Evi-
dence: B)
a. Base the target intensity of anticoagulation on the
particular type of prosthesis, but it should not be
less than INR 2 to 3. (Level of Evidence: B)
Class IIa
1. Target a lower INR of 2 (range 1.6 to 2.5) for
primary prevention of ischemic stroke and systemic
embolism in patients over 75 years old considered at
increased risk of bleeding complications but without
frank contraindications to oral anticoagulant ther-
apy. (Level of Evidence: C)
2. Manage antithrombotic therapy for patients with
atrial flutter, in general, as for those with AF. (Level
of Evidence: C)
3. Select antithrombotic therapy by the same criteria
irrespective of the pattern of AF (ie, for patients with
paroxysmal, persistent, or permanent AF). (Level of
Evidence: B)
Class IIb
1. Interrupt anticoagulation for a period of up to 1
week for surgical or diagnostic procedures that
carry a risk of bleeding, without substituting hepa-
rin in patients with AF who do not have mechanical
prosthetic heart valves. (Level of Evidence: C)
2. Administer unfractionated or low-molecular-weight
heparin intravenously or subcutaneously, respec-
tively in selected high-risk patients or when a series
of procedures requires interruption of oral antico-
agulant therapy for a period longer than 1 week.
(Level of Evidence: C)
3. Manage patients with CAD with anticoagulation
(INR 2 to 3) based on the same criteria used for
patients without CAD. (Level of Evidence: C)
a. A low dose of aspirin (less than 100 mg per day)
or clopidogrel (75 mg per day) may be given
concurrently with anticoagulation, but these
strategies have not been evaluated sufficiently
and may be associated with an increased risk of
bleeding. (Level of Evidence: C)
4. Treatment with aspirin is optional for primary
prevention of stroke in patients under age 60 years
without heart disease or risk factors for thrombo-
embolism (lone AF). (Level of Evidence: C)
Class III
Long-term anticoagulation for stroke prevention in
patients under 60 years of age without heart disease
(lone AF) and without risk factors for thromboembo-
lism. (Level of Evidence: C)
Recommendations for Antithrombotic
Therapy to Prevent Ischemic Stroke and
Systemic Embolism in Patients With AF
Undergoing Cardioversion
Class I
1. Administer anticoagulation therapy regardless of
the method (electrical or pharmacological) used to
restore sinus rhythm. (Level of Evidence: B)
2. Anticoagulate patients with AF lasting more than
48 h or of unknown duration for at least 3 to 4 weeks
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before and after cardioversion (INR 2 to 3). (Level of
Evidence: B)
3. Perform immediate cardioversion in patients with
acute (recent-onset) AF accompanied by symptoms
or signs of hemodynamic instability resulting in
angina pectoris, myocardial infarction, shock, or
pulmonary edema, without waiting for prior antico-
agulation. (Level of Evidence: C)
a. If not contraindicated, administer heparin con-
currently by an initial intravenous bolus injection
followed by a continuous infusion in a dose
adjusted to prolong the activated partial throm-
boplastin time at 1.5 to 2 times the reference
control value.
b. Next, provide oral anticoagulation (INR 2 to 3) for
a period of at least 3 to 4 weeks, as for patients
undergoing elective cardioversion. (Level of Evi-
dence: C)
c. Limited data from recent studies support subcuta-
neous administration of low-molecular-weight hep-
arin in this indication. (Level of Evidence: C)
4. Screening for the presence of thrombus in the LA or
LAA by TEE is an alternative to routine preantico-
agulation in candidates for cardioversion of AF.
(Level of Evidence: B)
TABLE 12. Recommended Doses of Drugs Proven Effective for Pharmacological Cardioversion of Atrial Fibrillation
Drug*
Route of
Administration Dosage** Potential Adverse Effects References
Amiodarone Oral Inpatient: 1.2–1.8 g per day in divided dose
until 10 g total, then 200–400 mg per day
maintenance or 30 mg/kg as single dose
Hypotension, bradycardia, QT
prolongation, torsade de pointes
(rare), GI upset, constipation,
phlebitis (IV)
92, 96, 124, 234,
251, 253–260
Outpatient: 600–800 mg per day divided dose
until 10 g total, then 200–400 mg per day
maintenance
Intravenous/oral 5–7 mg/kg over 30–60 min, then 1.2–1.8 g per
day continuous IV or in divided oral doses
until 10 g total, then 200–400 mg per day
maintenance
Dofetilide Oral Creatinine clearance
(mL/min)
Dose
(mcg BID)
QT prolongation, torsade de pointes;
adjust dose for renal function,
body size, and age
133, 225–229
greater than 60 500
40–60 250
20–40 125
less than 20 Contraindicated
Flecainide Oral 200–300 mg† Hypotension, rapidly conducting
atrial flutter
88–90, 92, 230–235
Intravenous 1.5–3.0 mg per kg over 10–20 min†
Ibutilide Intravenous 1 mg over 10 min; repeat 1 mg when
necessary
QT prolongation, torsade de pointes 236–241
Propafenone Oral 450–600 mg Hypotension, rapidly conducting
atrial flutter
90, 93, 94, 230,
233, 235,
242–252
Intravenous 1.5–2.0 mg per kg over 10–20 min†
Quinidine‡ Oral 0.75–1.5 g in divided doses over 6–12 h,
usually with a rate-slowing drug
QT prolongation, torsade de pointes,
GI upset, hypotension
88, 90, 91, 93, 242,
256, 257, 261,
262
GI indicates gastrointestinal; IV, intravenous; BID, twice a day.
*Drugs are listed alphabetically.
**Dosages given in the table may differ from those recommended by the manufacturers.
†Insufficient data are available on which to base specific recommendations for the use of one loading regimen over another for patients with ischemic heart disease
or impaired left ventricular function, and these drugs should be used cautiously or not at all in such patients.
‡The use of quinidine loading to achieve pharmacological conversion of atrial fibrillation is controversial, and safer methods are available with the alternative agents
listed in the table. Quinidine should be used with caution.
TABLE 13. Recommendations for Use of Pharmacological
Agents to Control the Rate of Ventricular Responses to
Atrial Fibrillation
Drug*
Route of
Administration
Type of
Recommendation
Level of
Evidence
Diltiazem Intravenous I A
Esmolol Intravenous I A
Verapamil Intravenous or oral I A
Other
beta-blockers
Intravenous or oral I B
Digoxin Intravenous or oral IIa B
*The doses of medications used in these studies may not be the same as
those recommended by the manufacturers.
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a. Anticoagulate patients in whom no thrombus is
identified with intravenous unfractionated hepa-
rin by an initial bolus injection before cardiover-
sion, followed by a continuous infusion in a dose
adjusted to prolong the activated partial throm-
boplastin time at 1.5 to 2 times the reference
control value. (Level of Evidence: B)
b. Next, provide oral anticoagulation (INR 2 to 3)
for a period of at least 3 to 4 weeks, as for patients
undergoing elective cardioversion. (Level of Evi-
dence: B)
c. Limited data are available to support the subcu-
taneous administration of low-molecular-weight
heparin in this indication. (Level of Evidence: C)
d. Treat patients in whom thrombus is identified by
TEE with oral anticoagulation (INR 2 to 3) for at
least 3 to 4 weeks before and after restoration of
sinus rhythm. (Level of Evidence: B)
Class IIb
1. Cardioversion without TEE guidance during the
first 48 h after the onset of AF. (Level of Evidence: C)
a. In these cases, anticoagulation before and after
cardioversion is optional, depending on assessment
of risk. (Level of Evidence: C)
2. Anticoagulate patients with atrial flutter undergoing
cardioversion in the same way as for patients with
AF. (Level of Evidence: C)
Recommendations for Prevention and
Management of Postoperative AF
Class I
1. Treat patients undergoing cardiac surgery with an
oral beta-blocker to prevent postoperative AF, un-
less contraindicated. (Level of Evidence: A)
2. In patients who develop postoperative AF, achieve
rate control by administration of AV nodal blocking
agents. (Level of Evidence: B)
Class IIa
1. Administer sotalol or amiodarone prophylactically
to patients at increased risk of developing postoper-
ative AF. (Level of Evidence: B)
2. Restore sinus rhythm in patients who develop post-
operative AF by pharmacological cardioversion with
ibutilide or direct-current cardioversion, as recom-
mended for nonsurgical patients. (Level of Evidence:
B)
3. In patients with recurrent or refractory postopera-
tive AF, attempt maintenance of sinus rhythm by
administration of antiarrhythmic medications, as
recommended for patients with CAD who develop
AF. (Level of Evidence: B)
4. Administer antithrombotic medication in patients
who develop postoperative AF, as recommended for
nonsurgical patients. (Level of Evidence: B)
TABLE 14. Recommendations for Antithrombotic Therapy in Patients With Atrial Fibrillation
Based on Thromboembolic Risk Stratification
Patient Features Antithrombotic Therapy
Grade of
Recommendation
Age less than 60 years
No heart disease (lone AF)
Aspirin (325 mg daily) or no therapy I
Age less than 60 years
Heart disease but no risk factors*
Aspirin (325 mg daily) I
Age greater than or equal to 60 years
No risk factors*
Aspirin (325 mg daily) I
Age greater than or equal to 60 years
With diabetes mellitus or CAD
Oral anticoagulation (INR 2.0–3.0) I
Addition of aspirin, 81–162 mg daily is optional IIb
Age greater than or equal to 75 years
especially women
Oral anticoagulation (INR ’2.0) I
HF
LV ejection fraction less than or equal
to 0.35
Thyrotoxicosis
Hypertension
Oral anticoagulation (INR 2.0–3.0) I
Rheumatic heart disease
(mitral stenosis)
Prosthetic heart valves
Prior thromboembolism
Persistent atrial thrombus on TEE
Oral anticoagulation
(INR 2.5–3.5 or higher may be appropriate)
I
*Risk factors for thromboembolism include HF, LV ejection fraction less than 0.35, and history of hypertension.
AF indicates atrial fibrillation; CAD, coronary artery disease; HF, heart failure; INR, international normalized ratio; LV,
left ventricular; and TEE, transesophageal echo.
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Recommendations for Management of
Patients With AF and Acute
Myocardial Infarction
Class I
1. Electrical cardioversion for patients with severe
hemodynamic compromise or intractable ischemia.
(Level of Evidence: C)
2. Intravenous administration of digitalis or amioda-
rone to slow a rapid ventricular response and im-
prove LV function. (Level of Evidence: C)
3. Intravenous beta-blockers to slow a rapid ventricu-
lar response in patients without clinical LV dysfunc-
tion, bronchospastic disease, or AV block. (Level of
Evidence: C)
4. Heparin for patients with AF and acute MI, unless
contraindications to anticoagulation are present.
(Level of Evidence: C)
Class III
1. Administer type IC antiarrhythmic drugs in patients
with AF in the setting of acute myocardial infarc-
tion. (Level of Evidence: C)
Recommendations for Management of AF and
Ventricular Preexcitation
Class I
1. Catheter ablation of the accessory pathway in symp-
tomatic patients with AF who have WPW syndrome,
particularly those with syncope due to rapid heart
rate or those with a short bypass tract refractory
period. (Level of Evidence: B)
2. Immediate electrical cardioversion to prevent ven-
tricular fibrillation in patients with WPW in whom
AF occurs with a rapid ventricular response associ-
ated with hemodynamic instability. (Level of Evi-
dence: B)
3. Intravenous procainamide or ibutilide in an attempt
to restore sinus rhythm in patients with WPW in
whom AF occurs without hemodynamic instability
in association with a wide QRS complex on the ECG
(greater than or equal to 120 ms in duration). (Level
of Evidence: C)
Class IIb
1. Administer intravenous quinidine, procainamide, di-
sopyramide, ibutilide, or amiodarone to hemody-
namically stable patients with AF involving conduc-
tion over an accessory pathway. (Level of Evidence:
B)
a. Immediate cardioversion is required when very
rapid tachycardias or hemodynamic instability
occurs in patients with AF involving conduction
over an accessory pathway. (Level of Evidence: B)
Class III
Intravenous administration of beta-blocking agents,
digitalis glycosides, diltiazem, or verapamil in patients
with WPW syndrome who have preexcited ventricular
activation in AF. (Level of Evidence: B)
Recommendations for Management of AF in
Patients With Hyperthyroidism
Class I
1. Administer a beta-blocker as necessary to control
the rate of ventricular response in patients with AF
complicating thyrotoxicosis, unless contraindicated.
(Level of Evidence: B)
2. In circumstances when a beta-blocker cannot be
used, administer a calcium channel antagonist (dil-
tiazem or verapamil) to control the ventricular rate.
(Level of Evidence: B)
3. In patients with AF associated with thyrotoxicosis,
use oral anticoagulation (INR 2 to 3) to prevent
thromboembolism, as recommended for AF patients
with other risk factors for stroke. (Level of Evidence:
C)
a. Once a euthyroid state is restored, recommenda-
tions for antithrombotic prophylaxis are the same
as for patients without hyperthyroidism. (Level of
Evidence: C)
Recommendations for Management of AF
During Pregnancy
Class I
1. Control the rate of ventricular response with
digoxin, a beta-blocker, or a calcium channel antag-
onist. (Level of Evidence: C)
2. Electrical cardioversion in patients who become
hemodynamically unstable due to the dysrhythmia.
(Level of Evidence: C)
3. Administer antithrombotic therapy (anticoagulant
or aspirin) throughout pregnancy to all patients with
AF (except those with lone AF). (Level of Evidence: C)
Class IIb
1. Attempt pharmacological cardioversion by adminis-
tration of quinidine, procainamide, or sotalol in
hemodynamically stable patients who develop AF
during pregnancy. (Level of Evidence: C)
2. Administer heparin to patients with risk factors for
thromboembolism during the first trimester and last
month of pregnancy. Unfractionated heparin may be
administered either by continuous intravenous infu-
sion in a dose sufficient to prolong the activated
partial thromboplastin time to 1.5 to 2 times the
control (reference) value or by intermittent subcu-
taneous injection in a dose of 10,000 to 20,000 U
every 12 h, adjusted to prolong the mid-interval (6 h
after injection) activated partial thromboplastin
time to 1.5 times control. (Level of Evidence: B)
a. Limited data are available to support the subcu-
taneous administration of low-molecular-weight
heparin for this indication. (Level of Evidence: C)
3. Administer an oral anticoagulant during the second
trimester to patients at high thromboembolic risk.
(Level of Evidence: C)
Recommendations for Management of AF in
Patients With HCM
Class I
Treat patients with HCM who develop AF with oral
anticoagulation (INR 2 to 3), as recommended for
other high-risk patients for prevention of thromboem-
bolism. (Level of Evidence: B)
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Class IIa
Antiarrhythmic medications to prevent recurrences.
Available data are insufficient to recommend one
agent over another in this situation, but disopyramide
and amiodarone are generally preferred. (Level of
Evidence: C)
Recommendations for Management of AF in
Patients With Pulmonary Diseases
Class I
1. In patients who develop AF during an acute pulmo-
nary illness or exacerbation of chronic pulmonary
disease, correction of hypoxemia and acidosis are the
primary therapeutic measures. (Level of Evidence:
C)
2. In patients with obstructive pulmonary disease who
develop AF, a calcium channel antagonist agent
(diltiazem or verapamil) is preferred for ventricular
rate control. (Level of Evidence: C)
3. Attempt electrical cardioversion in patients with
pulmonary disease who become hemodynamically
unstable due to AF. (Level of Evidence: C)
Class III
1. Use of theophylline and beta-adrenergic agonist
agents in patients with bronchospastic lung disease
who develop AF. (Level of Evidence: C)
2. Use of beta-blockers, sotalol, propafenone, and
adenosine in patients with obstructive lung disease
who develop AF. (Level of Evidence: C)
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